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The synthesis and biological evaluation of a series of novel, selective inhibitors of isoenzyme 1
of human 5R-reductase (5RR) (EC 1.3.99.5) are reported. The inhibitors are 4aH- (19-29) or
1H-tetrahydrobenzo[c]quinolizin-3-ones (35-47) bearing at positions 1, 4, 5, and 6 a methyl
group and at position 8 a hydrogen, methyl group, or chlorine atom. All these compounds were
tested toward 5RR-1 and 5RR-2 expressed in CHO cells (CHO 1827 and CHO 1829, respectively)
resulting in selective inhibitors of the type 1 isoenzyme, with inhibitory potencies (IC50) ranging
from 7.6 to 9100 nM. The inhibitors of the 4aH-series, having a double bond at position 1,2,
were generally less active than the corresponding inhibitors of the 1H-series having the double
bond at position 4,4a on the A ring. The presence of a methyl group at position 4 (as in
compounds 39-40 and 45-47), associated with a substituent at position 8, determined the
highest inhibition potency (IC50 from 7.6 to 20 nM). Compounds 39 and 40, having Ki values
of 5.8 ( 1.8 and 2.7 ( 0.6 nM, respectively, toward 5RR-1 expressed in CHO cells, were also
tested toward native 5RR-1 in human scalp and 5RR-2 in human prostate homogenates, in
comparison with finasteride and the known 5RR-1-selective inhibitor LY191704, and their
mechanism of inhibition was determined. They both inhibited the enzyme through a reversible
competitive mechanism and again were selective inhibitors of 5RR-1 with IC50 values of 41
nM. These specific features make these inhibitors suitable candidates for further development
as drugs in the treatment of DHT-dependent disorders such as acne and androgenic alopecia
in men and hirsutism in women.
Introduction
Dihydrotestosterone (DHT), the most potent circulat-
ing androgen hormone, is produced by the NADPH-
dependent, stereoselective reduction of testosterone (T)
under catalysis of the enzyme steroid 5R-reductase
(5RR) (EC 1.3.99.5).1,2 The DHT production is in many
cases related to the maintenance of some pathological
human diseases and endocrine disorders,3-8 so that the
use of 5RR inhibitors for the possible control or sup-
pression of DHT formation, without significant changes
in the circulating testosterone, became some years ago
a therapeutic target for the treatment of benign prostate
hyperplasia (BPH), androgenic alopecia, and acne in
men and hirsutism in women.9,10
Because of the discovery that two different DNA-
encoded isoenzymes of 5RR, named type 1 and type 2
(5RR-1 and 5RR-2), transform T into DHT with different
efficacy and that these two isozymes are not equally
distributed in the human tissues, 5RR-1 being present
mainly in scalp, skin, and liver, and 5RR-2 in the
prostate, different therapeutic approaches were later
developed. The synthesis and use of selective 5RR-2
inhibitors was initially envisioned for the specific treat-
ment of a prostate disease such as BPH, culminating
with the discovery of the first class of steroidal 5RR
inhibitors, the 4-azasteroids, and the introduction on the
market by Merck of finasteride (Proscar) (Figure 1), the
first drug for BPH treatment based on the concept of
5RR inhibition.11 However, after the observation that
finasteride was not equally efficacious in all treated
patients and that only in 30-40% of the treated cases
the circulating level of DHT decreases up to 20% of the
basal level,12 the synthesis and use of double 5RR-1 and
5RR-2 inhibitors became a therapeutic model to com-
pletely reducing the circulating DHT. This new ap-
proach has brought to development by Glaxo of dutas-
teride (Figure 1), a double inhibitor which entered phase
III clinical trials in 1997 and presumably will be on the
market for the treatment of BPH in 2000-2001.13
Although the role of 5RR-1 is not completely clear,
its diffuse presence in the scalp and skin of men
suffering from alopecia or acne and skin of women
suffering from hirsutism and polycistic ovarian syn-
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drome (PCOS) suggested a strong implication of 5RR-1
in these disorders.14 Therefore, the possibility of reduc-
ing the DHT level in those tissues by using selective
5RR-1 inhibitors (not affecting 5RR-2, mainly located in
prostate tissue) could be a new therapeutic approach
for the treatment of the above skin disorders.15 In
particular, the use of a “pure” 5RR-1 inhibitor is es-
sential for the treatment of hirsutism and PCOS be-
cause of the well-known risks of pseudohermafroditism
for the male fetus associated with 5RR-2 blockade in
pregnant women.16 To date, few compounds (one of
them, a nonsteroidal benzoquinoline synthesized by Eli-
Lilly, LY191704, is reported in Figure 1) have been
reported to have this selectivity but their clinical
development has not yet reached completion.17
On the basis of the above considerations, we started
some years ago a project aimed at the design and
synthesis of new inhibitors of 5RR-1 and 5RR-2,18-22
focusing in particular on the development of selective
5RR-1 inhibitors. We thus discovered that 19-nor-10-
azasteroids (Figure 1), designed by us as possible mimics
of a substrate-like transition state involved in the T to
DHT reduction, were dual inhibitors of 5RR, with a
potency tightly dependent on the presence, position, and
number of unsaturations on the A-C rings, as well as
the type of substituent at position 17.18
The observation that an increase of potency could be
associated with the presence of unsaturations on the C
ring, which determined a certain flatness of the aza-
steroidal skeleton, prompted us to design a novel class
of nonsteroidal inhibitors based on the benzo[c]quin-
olizin-3-ones structure (Figure 1).23,24 These compounds,
while maintaining the A ring enaminone moiety as an
essential feature of the 19-nor-10-azasteroids, lacked the
D ring and incorporated a benzene ring in place of the
C ring to have a more planar overall structure. In
analogy to Eli Lilly compounds and on the basis of the
above observations on 19-nor-10-azasteroids, we antici-
pated that these novel compounds could be selective
inhibitors of 5RR-1. In the present paper we therefore
describe the synthesis and structure-activity relation-
ship (SAR) of a series of benzo[c]quinolizin-3-ones 1-47
(Chart 1), differentiated by the presence and position
Figure 1.
Chart 1. Compounds of the 1H- and 4aH-Series
Benzo[c]quinolizin-3-ones Journal of Medicinal Chemistry, 2000, Vol. 43, No. 20 3719
of double bonds on the A ring and the type and number
of substituents introduced at positions 1, 4, 5, 6, and 8,
which resulted in potent and selective 5RR-1 inhibitors.
Chemistry
The preparation of the new class of benzo[c]quinolizin-
3-one inhibitors 1-47 required the study and develop-
ment of a synthetic strategy different from that em-
ployed in the synthesis of 19-nor-10-azasteroids. The
latter were in fact prepared through the tandem ther-
mal rearrangement-annulation of suitably functional-
ized isoxazoline-5-spirocyclopropanes,18,25 a methodology
developed in our laboratory which allows the sequential
construction of the A and B rings of the azasteroids
(Scheme 1). However it is a matter of course that this
procedure is inapplicable to the synthesis of benzo[c]-
quinolizin-3-ones due to the presence of an aromatic C
ring in the structure.
As an alternative to the isoxazoline methodology, we
recently reported a different synthesis of 19-nor-10-
azasteroids based on the TMSOTf-promoted tandem
Mannich-Michael reaction of 2-silyloxy-1,3-dienes with
N-(acyloxy)iminium ions generated in situ from the
corresponding N-Boc-R-ethoxy derivatives20-22 (Scheme
1). If applied to the synthesis of benzo[c]quinolizinones
1-47 (Scheme 2), this methodology would require the
preparation, from lactams 48-53, of bicyclic N-Boc-R-
ethoxy quinolines 60-65 to be reacted in turn with the
suitable silyloxydienes 66-69 in the presence of a Lewis
acid. This would generate the corresponding iminium
ion which undergoes tandem Mannich-Michael attack
by the silyloxydiene. In the case Danishefsky’s diene 67
(R1 ) OMe, R2 ) H) the reaction would lead directly to
1,2-unsaturated compounds 19-34 (wherein R1 ) H,
R2 ) H); otherwise oxidation of intermediates 1-18 is
necessary to introduce a double bond that conjugates
the bridgehead N and the 3-oxo group. As we have
already found in 19-nor-10-azasteroids, the lack of
conjugation between N and CdO causes a loss of
inhibitory potency, and this, if the inhibition mechanism
is similar for the two classes of compounds, is likely to
occur also in benzo[c]quinolizinones 1-18.
The synthesis of N-Boc-R-ethoxyquinolines 60-65 is
reported in Scheme 3. Lactams 49-53 were prepared
according to known procedures,26 whereas lactam 48
(R3,R4,R5 ) H) is commercially available. Aldehyde 70
(Scheme 3), treated with 2-(triphenylphosphanylidene)-
propionic acid methyl ester27 gave cynnamate 71 as a
mixture of diastereoisomers in 90% yield, which was
converted into 3-methyl-substituted lactam 51 by hy-
drogenation over PtO2 in AcOH. 4-Substituted anilines
72-73 were reacted with 3-chloropropanoyl or 3-chlo-
robutanoyl chlorides to give the corresponding â-chlo-
roamides 74-77 in quantitative yield. Lactams 49-50
and 52-53 were obtained after the intramolecular
Friedel-Craft alkylation that amides 74-77 underwent
in the presence of AlCl3 at 120-130 °C. In the case of
6-methyl-substituted amides 74 and 76, a strict control
of the temperature was necessary to avoid migration of
the methyl group on the aromatic ring and thus the
formation of isomers. After protection of N atom as
N-Boc to give compounds 54-59, reduction of the 2-oxo
group by NaBH4 in ethanol at -25 °C, followed by acidic
quench with 2 N HCl in ethanol, afforded N-Boc-2-
ethoxy derivatives 60-65 in 94-100% overall yield. In
the case of 3- and 4-methyl-substituted derivatives 63-
65, these compounds were obtained as 1:1 mixtures of
diastereoisomers.
In a previous communication23 we have reported that
TMSOTf catalyzes the tandem Mannich-Michael cy-
clization of unsubstituted N-t-Boc derivative 60 (X,R )
H) with silyloxydienes 66 (R1 ) R2 ) H) and 67 (R1 )
OMe, R2 ) H) providing benzo[c]quinolizin-3-ones 1 and
19 in moderate yields. To extend this methodology to
N-Boc-R-ethoxy derivatives such as 62, 63, or 65,
bearing a chlorine atom on the benzene ring, we studied
Scheme 1 Scheme 2
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the use of different Lewis acids to promote the formation
of N-(acyloxy)iminium ions, finding out that TiCl4
promoted the iminium ion formation and the succeeding
cyclization step better than TMSOTf. The new proce-
dure applied to N-Boc-R-ethoxy derivative 62 (X ) Cl,
R ) H) and diene 66 afforded 3 (X ) Cl, R ) H) in 34%
yield, whereas the same compound was obtained in 17%
yield employing TMSOTf as a Lewis acid.24
The TiCl4 methodology was applied to the synthesis
of 8-H-, 8-Cl-, and 8-CH3-substituted benzo[c]quinoliz-
inones 1-3, 10-12, 19, and 27 (Scheme 4), bearing no
substituents on the A ring and therefore deriving from
cyclization of 60-65 with Danishefky diene 67 and
2-trimethylsilyloxy-1,3-butadiene (66). Only in the case
of compound 2 the TMSOTf procedure furnished higher
yield (44%) than TiCl4.
The reaction of 3- and 4-substituted iminium ions
from 63-65 with diene 66 was stereoselective, providing
the isomer with the methyl group and the bridgehead
4a proton in a cis relative position as the major product.
These (and the following) stereochemical assignments
were possible by inspection of the coupling constants
in the 1H NMR spectrum of the saturated and, then,
the corresponding ¢1- or ¢4-oxidized derivatives. A
complete discussion on the attribution of the relative
stereochemistry is reported in the Supporting Informa-
tion. Compounds 10-12 were isolated in 29-35% yield
after chromatographic purification, while their trans
isomers were only detected (<3%) by 1H NMR analysis
of the crude reaction mixtures. The reactions of 63 and
64 with Danishefsky’s diene 67, which afforded ¢1-
unsaturated compounds 27 (29%) and 19 (28%), oc-
curred with similar stereoselectivity. Since strong Lewis
acids are able to remove the N-t-Boc protection, the
stereochemical outcome of these reactions could be
explained by the formation, after the addition of TiCl4
to the R-ethoxy carbamate, of a planar imine in which
the N atom coordinates a titanium complex.21 The
methyl group at position 3 or 4 then leads to a preferred
less hindered anti attack by the dienes.
The oxidation of compounds 1-3 and 10-12 to the
1,2- or 4,4a-unsaturated analogues (Scheme 4) was
performed by treatment with Hg(AcO)2 as already
reported for the 19-nor-10-azasteroid synthesis.28 As an
alternative, after formation of the corresponding silyl
enol ethers by treatment with LDA and TMSCl in THF
at -78 °C, oxidation can be achieved by employing DDQ
at room temperature.29 Usually, the latter conditions
afforded almost equimolar amounts of ¢1- and ¢4-
isomers (as in the oxidation of 1 and 2) and lower yields
than Hg(OAc)2, which instead provided always mixtures
containing compounds of the 1H-series (35, 37, 41-43)
Scheme 3a
a (a) Ph3PdC(Me)COOMe, toluene, 80 °C, 3 h; (b) H2, 10 atm, PtO2, AcOH, 60 °C, 14 h; (c) (BOC)2O, Et3N, DMAP, CH2Cl2, 18 h, 25 °C;
(d) NaBH4, EtOH, -25 °C, 2-5 h, then 2 N HCl in EtOH, pH 3-4, -25 f 0 °C, 1.5-7 h; (e) RCH(Cl)CH2COCl, acetone, reflux, 1 h; (f)
AlCl3, 120-160 °C, 3-24 h.
Scheme 4a
a (a) 1 M TiCl4 in CH2Cl2, -30 °C, 10 min, then 66 or 67,
-30 f 25 °C, 30 min; then NaHCO3 (satd), 45 min; (b) methyl
vinyl ketone, TMSOTf, Et3N, CH2Cl2, 0 °C, 30 min; then 60-65,
TMSOTf, 0 f 25 °C, 45 min; then NaHCO3, 25 °C, 36 h; (c)
Hg(OAc)2, EDTA tetrasodium salt, 5-50% CH3COOH (aq), 90 °C,
2 h; (d) LDA, Me3SiCl, THF, -78 f 25 °C; then DDQ, 25 °C, 18 h.
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as the major isomers. On the other hand, complete
oxidation of the A ring was in some cases observed
(oxidation of 10 and the 4-5 mixture) under the more
drastic conditions required with mercuric acetate, and
compounds 79 (Scheme 4) and 80 (Scheme 6) were
obtained in 16 and 12% yield.
While employing TiCl4 as a Lewis acid requires the
addition of a pre-formed pure diene to the reaction
mixture, in the TMSOTf-promoted Mannich-Michael
cyclization process the reacting silyloxydiene may be
generated in situ using the corresponding alkyl vinyl
ketone. Thus, we found more convenient to employ the
TMSOTf procedure in the preparation of 1- and 4-meth-
yl-substituted benzo[c]quinolizin-3-ones (Schemes 5 and
6) by the in situ generation of 4-methyl-2-(trimethylsi-
lyloxy)-1,3-butadiene (68) from 3-penten-2-one with the
TMSOTf/Et3N system in dichloromethane. The addition
of 62 and a further amount of TMSOTf (Scheme 5) to
the solution of 68, afforded an approximatively 1:1
mixture of 1-methyl-substituted compounds 13 and 14,
together with a smaller amount of open chain product
78. Treatment of this mixture with TiCl4 caused com-
plete cyclization of 78 to a mixture of 13 and 14.
Oxidation of 14 was carried out by Hg(OAc)2, providing
¢4-compound 44 in 96% yield and its ¢1-isomer 30 in
4% yield (18% and 9% yield, respectively, by the DDQ
oxidation).
With a similar procedure, R-ethoxy carbamates 60-
62 were reacted with silyloxydiene 69 derived from
1-penten-3-one (Scheme 6), yielding 4-methyl-substi-
tuted compounds 4-5, 6-7, and 8-9 in 22-30% yield
as 4R/â-variable mixtures. Only in the case of the 6-7
mixture were we able to obtain, after chromatograophy,
pure â-isomer 7. A portion of each mixtures was then
oxidized by Hg(OAc)2, affording ¢4-unsaturated com-
pounds 38-40 (35-71%), whereas another portion was
subjected to the DDQ procedure, obtaining only ¢1-
unsaturated compounds 22-25 in 44-46% yield as
epimeric 4R/â-mixtures. Compound 26 was obtained as
a single 4â-isomer, but taking into account the very low
final yield (18%), the other isomer might have been lost
during the chromatographic purification.
Diene 69 was employed for the synthesis of 4,5- and
4,6-dimethyl-substituted benzo[c]quinolizinones 15-18
(Scheme 7) according to the TMSOTf procedure. How-
ever, very complex isomeric mixtures were obtained
after reaction of 69 with 3- and 4-methyl-substituted
carbamates 63-65. A careful chromatographic separa-
tion allowed the recovery of the 1:2 mixture of epimers
15 and 16, having the methyl at C5 in a cis relative
position with the 4a-H proton, but in low yield (20%).
Both 4,6-dimethyl derivatives 17 (X ) Me) and 18 (X )
Cl) were obtained in 14% yield as mixtures in which
the diastereoisomer having both the methyl groups R
orientated with respect to the 4a-H hydrogen was
prevailing. Usual oxidation of the 15/16 mixture by Hg-
(OAc)2 yielded ¢4-compound 45 (14%) besides the 1:2
mixture of ¢1-isomers 31 and 32 (11%) which were
separated after repeated chromatographies. Similarly,
oxidation of 17 and 18 gave rise to ¢4-compounds 46
(27%) and 47 (34%), respectively, together with ¢1-
isomers 33 and 34.
The stereochemical outcome of the reaction of 69 with
the iminium ions generated from 63 seems to be in
accordance with the initial anti approach of the diene
as already discussed, as well as the formation of
compounds 17 and 18, which apparently derive from the
anti approach of 69 to the iminium ions from 64 and
65.
Finally, also the HCl salts of two unsaturated benzo-
[c]quinolizin-3-ones were prepared by dissolving com-
pounds 38 and 40 in a solution of HCl in anhydrous
methanol, obtaining after evaporation of the solvent
salts 81 and 82, both tested toward 5RR-1 and 5RR-2.
Results
Inhibition toward Human Recombinant 5RR-1
and 5RR-2 in CHO Cells. Most of the synthesized
compounds were tested toward the two human recom-
binant isozymes of 5RR to evaluate the inhibitory
potency and isozyme selectivity using finasteride as a
control (Table 1). The assays were performed using
stably transfected CHO cells (CHO 1827 for 5RR-1 and
CHO 1829 for 5RR-2, respectively)30 incubated for 30
min with [3H]testosterone at the Km concentration (2
Scheme 5a
a (a) 3-Penten-2-one, TMSOTf, Et3N, CH2Cl2, 0 °C, 30 min, then
62, TMSOTf, 0 f 25 °C, 45 min, then NaHCO3, 25 °C, 36 h; (b) 1
M TiCl4 in CH2Cl2, rt, 3 h, then NaHCO3(satd), 45 min; (c)
Hg(OAc)2, EDTA tetrasodium salt, 45% CH3COOH(aq), 90 °C, 2
h; (d) LDA, Me3SiCl, THF, -78 f 25 °C, then DDQ, 25 °C, 18 h.
Scheme 6a
a (a) 1-Penten-3-one, TMSOTf, Et3N, CH2Cl2, 0 °C, 30 min, then
60-62, TMSOTf, 0 f 25 °C, 45 min, then NaHCO3, 25 °C, 36 h;
(b) LDA, Me3SiCl, THF, -78 f 25 °C, then DDQ, 25 °C, 18 h; (c)
Hg(OAc)2, EDTA tetrasodium salt, 5-8% CH3COOH(aq), 90 °C,
2 h.
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íM for 5RR-1 and 0.2 íM for 5RR-2) and each inhibitor
in the 10-9-10-5 M concentration range. Data were
processed with the program ALLFIT31 using the four
parameter logistic equation to calculate the IC50 values.
The interassay reproducibility of the method was good
as assessed by calculating the mean IC50 of finasteride:
911 ( 85 nM (CV% ) 9.4, n ) 15) and 21 ( 1.8 nM
(CV% ) 8.6, n ) 12) for 5RR-1 and 5RR-2, respectively,
consistent with the established selectivity reported for
the inhibitor.15a All the tested molecules resulted as
selective inhibitors of 5RR-1 having IC50 values (Table
1) ranging from 7.6 nM to 9.1 íM, whereas they
displayed very poor or no inhibition toward 5RR-2.
The inhibitors belonging to the 1H-series were more
potent than those of the 4aH-series. For further studies
we selected the very potent compounds 39 and 40,
belonging to the 1H-series, which being achiral com-
pounds do not require a separation of enantiomers as
for many of the other inhibitors. The Ki values of 40
and 39 were then determined using again CHO 1827
intact cells, and a competitive mechanism of action was
demonstrated. Also for these experiments finasteride
was used as a control inhibitor, resulting in a competi-
tive inhibitor. The Ki values were 2.7 ( 0.6 and 5.8 (
1.8 nM, respectively, for 40 and 39 and 366 ( 186 nM
for finasteride, the latter in good agreement with the
reported value.30
The mechanism of action of the most potent inhibitor
40 was studied on recombinant 5RR-1 isozyme using
intact CHO 1827 transfected cells. To demonstrate the
reversibility of inhibition, we applied to our cell system
a method recently described by Azzolina et al.32 for the
elucidation of the mechanism of action of finasteride on
the rat 5RR-1 and 5RR-2 isozymes. Intact cells were
maintained in contact with the inhibitor at the IC50
concentration, and the reduction of enzymatic activity
was monitored at different times versus a control. After
1 h the medium containing the inhibitor was removed;
cells were washed with phosphate-buffered saline (PBS)
solution and incubated without the inhibitor. If the
enzymatic activity is restored at the control level the
inhibitor is considered reversible. Finasteride, used as
Scheme 7a
a (a) 1-Penten-3-one, TMSOTf, Et3N, CH2Cl2, 0 °C, 30 min, then 63-65, TMSOTf, 0 f 25 °C, 45 min, then NaHCO3, 25 °C, 36 h; (b)
Hg(OAc)2, EDTA tetrasodium salt, 50% CH3COOH(aq), 90 °C, 2 h.
Table 1. Inhibition of Compounds of the 1H- and 4aH-Series toward Recombinant 5RR-1 Expressed in CHO Cells
compd R1 R2 R3 R4 R5 IC50 (nM) compd R1 R2 R3 R4 R5 IC50 (nM)
19 H H H H H 5130 ( 130 35 H H H H H 298 ( 75
20 H H H H Me 176 ( 17 36 H H H H Me 376 ( 185
21 H H H H Cl 459 ( 118 37 H H H H Cl 49 ( 19
22 H Me (R) H H H 2700 ( 300 38 H Me H H H 185 ( 62
23 H Me (â) H H H 4300 ( 400 39 H Me H H Me 20 ( 8
5.8 ( 1.8a
24 H Me (R) H H Me 137 ( 58 40 H Me H H Cl 7.6 ( 0.9
2.7 ( 0.6a
25 H Me (â) H H Me 312 ( 23 41 H H Me H Cl 346 ( 185
26 H Me (â) H H Cl 141 ( 24 42 H H H Me Me 14.3 ( 5.9
27 H H Me (R) H Cl 9100 ( 500 43 H H H Me Cl 14.4 ( 3.4
29 H H H Me (R) Cl 188 ( 42 44 Me H H H Cl 204 ( 49
45 H Me Me H Cl 15.6 ( 4.0
46 H Me H Me Me 15.8 ( 4.6
47 H Me H Me Cl 8.5 ( 2.1
a This is a Ki value.
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a control inhibitor, showed an irreversible behavior as
expected under these conditions, whereas 40 displayed
a reversible mechanism of action. In Figures 2 and 3
are reported the graphs of the experiments conducted
with 40 and finasteride.
Inhibitory Activity toward Native 5RR-1 and
5RR-2. To confirm the complete selectivity observed for
these compounds toward the recombinant enzymes, we
selected 39 and 40 for determining their inhibitory
activity and selectivity versus native 5RR-1 and 5RR-2
using human scalp and human prostate tissues, respec-
tively (Table 2).
To have an in vitro system representative of the in
vivo situation, we used the total tissue homogenate
without any fractionation. It is known that 5RR-2 is the
prevalent isozyme in prostate tissue, while 5RR-1 is
mainly expressed in scalp skin. However, the presence
of both 5RR isozymes in prostate tissue and also in scalp
skin has been recently documented (mRNA, expressed
protein, and functional protein).33 A major problem
arises from the lack of knowledge on the exact ratio of
the two isoenzymes within the different parts of the
tissues. For this reason, aimed at evaluating the specific
inhibition for each enzyme, we set the experimental
conditions to measure the activity of desired target
isozyme avoiding any possible interference due to the
presence of the other isoenzyme. As a control of the
assay selectivity, we tested finasteride which is a quite
selective 5RR-2 inhibitor and LY191704 (Figure 1) as a
completely selective 5RR-1 inhibitor.
The inhibition test against 5RR-2 in human prostate
homogenates was performed using a 50 nM testosterone
concentration; only 5RR-2 should be active at this
concentration because of the different Km values of the
two isozymes for the substrate (1.7 íM for 5RR-1 and
0.2 íM for 5RR-2). Under these experimental conditions
the IC50 value obtained for finasteride was 2.2 ( 0.2
nM, while LY191704 resulted inactive (only 19% inhibi-
tion at 10 íM). These results are in good agreement with
the data reported in the literature for 5RR-2 inhibition
of both compounds,11,17 assessing that in the above assay
only the type 2 isoenzyme was activated. Also com-
pounds 39 and 40 resulted inactive versus 5RR-2,
displaying only a 20% inhibition at 10 íM concentration.
By contrast, when performing the inhibition tests
with human scalp homogenates to measure the 5RR-1
inhibition, it is not possible to find a testosterone
concentration where only the 5RR-1 is active. Indeed,
at the micromolar concentration of testosterone required
for the activation 5RR-1, also 5RR-2 is active and works
at its maximum velocity. However, by adding finasteride
(10 nM) in all inhibition experiments, we were able to
selectively block the 5RR-2 activity without interfering
with the 5RR-1 activity. Thus, in this assay, the refer-
ence compound LY1917104 resulted active with an IC50
of 2.3 ( 1.4 nM, in good agreement with the value
reported for its 5RR-1 inhibition.17 Benzo[c]quinolizin-
ones 39 and 40 both displayed an IC50 value of 41 nM,
assessing that these compounds are therefore selective
and potent inhibitors of the native 5RR-1 present in the
scalp tissue.
Discussion
We have already reported in a previous communica-
tion23 on the inhibitory activity of two simple unsubsti-
tuted benzo[c]quinolizinone compounds (35 and 19)
toward both 5RR-1, expressed by transfected CHO cells,
and native 5RR-2, in human prostate homogenates.
Both compounds were selective 5RR-1 inhibitors with
IC50 values of 298 and 5130 nM, respectively, with ¢4-
compound 35 being about 17-fold more active than its
¢1-isomer 19.
The introduction of substituents on different positions
of the benzo[c]quinolizinone skeleton of 35 and 19
allowed us to obtain two classes (1H- and 4aH-series)
of compounds differing by the position of the double
bond on the A ring. In Table 1 the inhibition values of
¢1-compounds 19-29 and ¢4-compounds 35-47 toward
5RR-1 expressed in recombinant CHO cells are reported.
All of them were inactive toward 5RR-2 in CHO cells.
In general, the compounds of the 1H-series resulted
significantly more active than those of the 4aH-series,
Figure 2. Determination of the mechanism of inhibition for
compound 40: top lines, control; bottom lines, experiments
with inhibitor. Concentration of 40 was 10 nM.
Figure 3. Determination of the mechanism of inhibition for
finasteride: top lines, control; bottom lines, experiments with
inhibitor. Concentration of finasteride was 700 nM.
Table 2. Inhibition Activity toward Native 5RR-1 and 5RR-2
inhibition
compd 5RR-1a 5RR-2b
finasteride 2.2 ( 0.2 nMc
LY191704 2.3 ( 1.4 nMc,d 19% at 10 íM
39 41 ( 22 nMc,d 20% at 10 íM
40 41 ( 17 nMc,d 20% at 10 íM
a From human scalp homogenates. b From human prostate
homogenate. c IC50 value. d In these experiments 10 nM finasteride
was used to block 5RR-2 present in the scalp tissue.
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the IC50 values of the latter being approximately 10-
fold higher. In fact the inhibition values ranged from
137 to 9100 nM for the 4aH-compounds and from 7.6 to
376 nM for the 1H-compounds.
The presence of a substituent at position 8, for
instance a chlorine or methyl group, generally increased
the potency of the inhibitors in both series. Thus, in the
4aH-series compounds 20 (IC50 176 nM) and 21 (IC50
459 nM), bearing an 8-methyl and 8-chlorine, respec-
tively, were significantly more active than unsubstituted
compound 19 (IC50 5130 nM). Analogously, in the 1H-
series the chlorine atom at position 8, either alone or
in the presence of other substituents on the two ali-
phatic rings, increased noticeably the potency toward
5RR-1. Thus 8-Cl-substituted compounds 37 (IC50 49
nM) and 40 (IC50 7.6 nM) were significantly more active
than unsubstituted compound 35 (IC50 298 nM) and 38
(IC50 185 nM), respectively. Instead, the methyl group
at position 8 of compounds of the 1H-series was inef-
fective when alone, while it increased the potency if
combined with one or two methyl groups on the two
aliphatic rings. In fact, 8-methyl-substituted compound
36 (IC50 376 nM) was approximately as potent as the
unsubstituted compound 35 (IC50 298 nM), while the
modification of compound 38 (IC50 185 nM) by introduc-
ing a methyl group at position 8 led to the more potent
compound 39 having an IC50 of 20 nM.
The introduction of a methyl group at position 4 in
both series was effective in increasing the inhibitory
potency. The extent of the increase is more slight in the
4aH-series and higher in the 1H-series. In the 1H-series
the introduction of a methyl at 4 position determines a
strong increase of potency, in particular when the
8-position is substituted with a chlorine or methyl. Thus,
whereas 4-methyl derivative 38 displayed an inhibition
activity (IC50 185 nM) not too significantly different from
the unsubstituted compound 35 (IC50 298 nM), a very
strong increase of potency is observed in 8-chloro-4-
methyl derivative 40 (IC50 7.6 nM) and 4,8-dimethyl
derivative 39 (IC50 20 nM) with respect to the 4-methyl-
unsubstituted compounds 37 (IC50 49 nM) and 36 (IC50
376 nM), respectively.
The substitution with a methyl group at position 6
positively affected the potency of the inhibitors, al-
though more markedly in the 1H-series than in the 4aH-
series. So compounds 42 (IC50 14.3 nM) and 43 (IC50
14.4 nM) were significantly more active than the cor-
responding compounds 36 and 37, not substituted at
position 6 (compare also compounds 29 and 21 of the
4aH-series). The further substitution with a methyl
group at position 4 in trisubstituted compounds 46 (IC50
15.8 nM) and 47 (IC50 8.5 nM) maintained the inhibitory
activity compared to 6,8-disubstituted compounds 42
and 43.
The results discussed so far are consistent with those
reported for structurally related compounds,17 whose
potency toward 5RR-1 increased noticeably by introduc-
ing a methyl group at position 4 of the skeleton and a
chlorine at position 8. Also, the beneficial effect of the
methyl at position 6 seems consistent with the observa-
tion that the introduction of the same group on the
corresponding position 7 in 4-azasteroids increased their
5RR-1 selectivity.34 By contrast, the presence of a methyl
group at position 5 in general reduced the potency
unless it was associated to another methyl group at the
position 4. Finally, the introduction of a methyl at the
position 1 in 8-Cl-substituted compound 44 (IC50 204
nM) slightly decreased the activity toward 5RR-1 in
comparison with the homologous derivative 37 (IC50 49
nM).
In conclusion, the contemporaneous presence of the
methyl or chlorine substituent at position 8 and a
methyl group at the 4 or 6 position appears to be the
best combination for fitting the active site of the enzyme.
This is in accordance with the inhibition values obtained
in the Eli Lilly series in which the most potent inhibitor
bears a methyl on position 4 and a chlorine on position
8 (LY191704, Figure 1) and with the observation that
in the 4-azasteroid class the introduction of a methyl
at position 4 or 7 (equivalent to the 6 position of
benzoquinolizines) always increases the inhibition against
5RR-1. In Figure 4 a qualitative SAR analysis for the
inhibitors of the 1H-series is reported.
Among the saturated compounds which were inter-
mediates in the synthesis of the 1H- and 4aH-inhibitors,
we decided to evaluate the inhibitory potency of com-
pound 8 bearing a methyl on position 4 and a chlorine
on position 8 since these are the substituents leading
to the best inhibitors in both 1H- and 4aH-series. As
we have already observed for the 10-azasteroids, the
presence of a double bond allowing the conjugation
between the carbonyl group and the nitrogen atom is
an essential feature for having good inhibition values.
In fact, compound 8 had an IC50 of 478 ( 95 nM toward
5RR-1, with potency significantly lower than those
obtained for compounds 40 and 26.
In some of the oxidation reactions leading to the 1H-
series we have isolated also the 1,2- and 4,4a-unsatur-
ated compounds, in particular 4-Me-substituted com-
pound 80 and 8-Cl,5-Me-substituted compound 79.
These were tested toward both isozymes resulting as
selective, although very weak, inhibitors of 5RR-1 (80,
IC50 1.4 ( 0.2 íM; 79, 1.88 ( 0.3 íM). Also the HCl salts
of 38 and 40 were tested toward 5RR-1, but they did
not show any significant difference in the inhibitory
activity compared to their parent compounds.
To determine a possible model accounting for the
observed potency of benzo[c]quinolizin-3-ones, we per-
formed a complete conformational analysis on com-
pounds LY191704, 40, and 24 as already reported for
19-nor-10-azasteroids,19 i.e., a first exhaustive Monte
Carlo conformational search (MM2* force field, Macro-
Model software)35 followed by AM1 geometry optimiza-
Figure 4. Qualitative structure-activity relationship for ¢4-
benzo[c]quinolizin-3-ones as 5RR-1 inhibitors.
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tion (Spartan software).36 The AM1 calculation produced
two thermally accessible conformers for each compound,
having relative energies comprised in a range of only
1.2 kcal/mol with respect to the global minimum (Table
3). A third conformer of 24 was discarded because of its
higher energy (>3 kcal/mol with respect to the global
minimum). The conformers of each compound of the 1H-
series differed by the conformation of the A ring, which
was 1â,2R or 1R,2â, while the B ring had a fixed 6R-
sofa conformation (referring to the C3-C4-C4a-N11
mean plane).19 The interconversion barriers among the
conformers were also calculated as already described.19
The low values found (<3 kcal/mol) suggest that,
similarly to the 19-nor-10-azasteroids, 40 and 24 are
very flexible molecules in the A ring portion. The same
low conformational barrier was found for the Eli Lilly
compound. Eli Lilly’s researchers suggested that the
high inhibitory activity toward 5RR-1 isoenzyme of their
benzoquinoline compounds, such as LY191704, could be
associated to their extended planarity.37 We had also
already observed that among the 19-nor-10-azasteroid
inhibitors, those having a double bond at position 8(9),
i.e., between rings A and B, were more potent than the
corresponding compounds with the double bond at
position 9(11).18 This result appears to be in accordance
with the Eli Lilly’s researcher assumption, since the 8(9)
double bond forces the molecule to assume a more
planar structure.
An index of the planarity of the above inhibitors could
be obtained by calculating the average distance of all
the skeleton atoms from the mean plane of the molecule.
The global minimun conformer LY191704_I resulted as
the most planar, with an average distance of 0.178 Å.
Therefore, because of the highest potency and selectivity
of LY191704 toward 5RR-1 among the Eli Lilly inhibi-
tors, we may take conformer LY191704_I as a reference
structure and compare our benzo[c]quinolizin-3-ones
with it.
By the superposition of all the skeleton atoms of
LY191704_I and the predicted conformers of our benzo-
[c]quinolizin-3-one inhibitors, we found that 40_II was
the closest (rms ) 0.223) to LY191704_I (Figure 5). In
this case it was possible to observe a fair spatial
correspondence of skeleton atoms C2, C3, and C4 and,
as a consequence, of the carbonyl and methyl groups of
the two molecules, of atoms C5 and C6 of the B ring,
and of all atoms (included the chlorine one) of the
benzene ring. Incidentally, the two conformers of the
¢4-compound 40 were also the most planar among the
benzo[c]quinolizin-3-ones compounds (see Table 3).
Greater deviations were instead observed with the
compound of the 4aH-series when superimposing both
the conformers of 24 with LY191704_I (rms ) 0.270 and
0.300) (Figure 5). Therefore, the low potency of the 4aH-
inhibitors, if compared to the corresponding 1H-com-
pounds, could be explained on the basis of their less
extended planarity.38
If we now take 40_II as a reference conformer for the
inhibitors of 5RR-1, we can compare ¢8(9)- and ¢9(11)-
19-nor-10-azasteroids with that in order to find the
closest one in terms of extended planarity. The super-
position of the A and B rings of ¢8(9)- and ¢9(11)-10-aza-
3,17-androstenedione39 with the corresponding rings of
40_II (Figure 3) clearly resulted in a greater deviation
of the C ring of the ¢9(11)-azasteroids from the aromatic











LY191704_I -30.70 -46.3 +45.9 0.178
LY191704_II -30.04 +27.2 +50.2 0.253
40_I -8.07 1â,2R 6R-sofa +45.8 +45.6 0.204
40_II -6.86 1R,2â 6R-sofa -48.3 +48.1 0.182
24_I -3.12 +55.1 0.297
24_II -3.07 +38.6 0.415
a Averaged distance of all skeleton atoms from the mean plane of the molecule.
Figure 5. From the top: (a) superposition of the A rings of
conformers LY191704_I, 40_I, 40_II, and 24_I, showing a
remarkable deviation of 24_I from the reference conformer
LY191704_I; (b) superposition of all skeleton atoms of con-
formers LY191704_I and 40_II; (c) superposition of the A and
B rings of 40_II and the corresponding conformer of 10-
azaestra-4,8(9)-diene-3,17-dione; (d) superposition of the A and
B rings of 40_II and the corresponding conformer of 10-
azaestra-4,9(11)-diene-3,17-dione.
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ring of the benzo[c]quinolizinone conformer. This can
be quantified by calculating the average distances
between the corresponding pair of atoms C7/C14, C8/
C13, C9/C12, and C10/C11, which resulted in 0.856 and
0.404 Å for the ¢9(11)- and ¢8(9)-isomers, respectively.
The introduction of the 4-methyl group increases
dramatically the potency of both LY191704 and 40 with
respect to the 4-unsubstituted compound. It is possible
that a small hydrophobic pocket in the enzyme active
site accommodates this substituent. However, also
electronic effects could be taken into account to explain
the increase of potency. We have shown in a previous
work on 10-azasteroids18 that a growth of potency
toward both isoenzymes could be associated with the
increase of the electrostatic charge on the oxygen atom
at C3, which would favor the initial interaction with an
H-bond donor residue of the active site. The partial
charges of benzo[c]quinolizin-3-ones were determined by
ab initio HF-STO 3-21G(*) calculations. The substitution
of the C ring of the azasteroids with an aromatic ring
did not affect the negative partial charges on the oxygen
which was about -0.62 for compounds 35 and 37
unsubstituted at position 4 (the charge was -0.63 in
¢4(5)-10-azasteroids). When a methyl group was intro-
duced at position 4 the negative charge decreased to
-0.58 and -0.59 (Table 4), very close to the charge of
the oxygen atom in saturated 10-azasteroids. These last
were poor inhibitors of 5RR, and we justified this
observation with the decrease of negative charge on the
oxygen. On the basis of the current results, however, it
seems that the steric effects of the 4-methyl group in
the benzo[c]quinolizinones series are by far more im-
portant than the electronic ones, and the presence of a
hydrophobic pocket in the active site of the enzyme
which accommodates small alkyl groups appears con-
sequently possible.
Conclusion
In this paper we have reported on the synthesis and
biological evaluation of a series of potent and selective
inhibitors of 5RR-1, the isozyme involved in the trans-
formation of testosterone to dihydrotestosterone mainly
in human skin and scalp tissues and thus possibly
causing the development and maintenance of disorders
such as acne and androgenic alopecia in men and
hirsutism in women. The synthesized inhibitors are
benzo[c]quinolizin-3-ones derivatives bearing at position
1, 4, 5, and/or 6 a methyl group and at position 8, i.e.,
on the aromatic ring, a hydrogen, methyl group, or
chlorine atom. Depending on the position of the double
bond on the A ring, two classes of inhibitors can be
identified: i.e., those having the double bond at position
1,2 (4aH-series) and those having the double bond at
position 4,4a (1H-series). All these compounds were
tested toward 5RR-1 and 5RR-2 expressed in CHO cells
(CHO 1827 and CHO 1829, respectively) resulting in
selective inhibitors of the type 1 isoenzyme, with inhibi-
tory potencies (IC50) ranging from 7.6 to 9100 nM. The
inhibitors of the 4aH-series were generally less active
than the corresponding inhibitors of the 1H-series,
which have the double bond at position 4,4a on the A
ring, and this could be associated with the higher
extended planarity of the compounds belonging to the
latter series, as evidenced by a molecular modeling
study carried out in comparison with the known 5RR-
1-selective inhibitors LY191704. The most potent in-
hibitors had a chlorine atom (or a methyl group) at
position 8, although it was the presence of a methyl
group at position 4 (as in compounds 39-40 and 45-
47), associated with the substitution at position 8, that
determined the highest inhibition potency (IC50 from 7.6
to 20 nM). This suggests the presence of a small
hydrophobic pocket in the enzyme active site accom-
modating the methyl group at position 4 (the same
substitution is present in LY191704). The two not chiral
4-methyl-(1H)-2,3,5,6-tetrahydrobenzo[c]quinolizin-3-
ones 39 and 40, bearing at the 8 position a methyl group
or chlorine, respectively, were selected among the most
potent inhibitors as possible candidate for a lead
development. They both selectively inhibited 5RR-1
expressed in CHO 1827 cells through a reversible
competitive mechanism displaying Ki values of 5.8 and
2.7 nM for 39 and 40, respectively. When they were
tested toward native 5RR-1 in scalp homogenates and
5RR-2 in prostate homogenates, in comparison with
finasteride and the known 5RR-1-selective inhibitor
LY191704, both resulted as selective inhibitors of 5RR-1
in scalp with IC50 values of 41 nM, being inactive toward
5RR-2 present in human prostate tissue. Therefore, on
the basis of these results, these two new potent and
selective 5RR-1 inhibitors are the best candidates for
the development of a drug for the treatment of acne and
androgenic alopecia in men and hirsutism and polycystic
ovarian syndrome in women.
Experimental Section
All the reactions were performed under nitrogen, unless
otherwise stated. Chromatographic separations were per-
formed under pressure on silica gel using flash-column tech-
niques. Rf values refer to TLC carried out on 25-mm silica gel
plates (Merck F254), with the same eluant indicated for the
column chromatography. IR spectra were recorded on a Perkin-
Elmer 881 spectrophotometer in CDCl3 solution. 1H NMR (200
MHz) and 13C NMR (50.33 MHz) spectra were recorded on a
Varian XL 200 instrument in CDCl3 solution. Mass spectra
were carried out in EI at 70 eV on a 5790A-5970A Hewlett-
Packard and QMD 1000 Carlo Erba instruments. Microanaly-
ses were carried out with a Perkin-Elmer 240C elemental
analyzer. 2-(Triphenylphosphanylidene)propionic acid methyl
ester was prepared as reported.27 Diene 66 was prepared as
reported.40
6-Methyl-3,4-dihydroquinolin-2(1H)-one (49).26 To a
refluxing solution of p-toluidine 73 (10.7 g, 100 mmol) in
acetone (20 mL) was slowly added a solution of 3-chloropro-
panoyl chloride (5 mL, 50 mmol) in acetone (10 mL). Then the
solution was refluxed 1 h and finally cooled to room temper-
ature. The resulting suspension was transferred into a flask
containing a solution of 6 N HCl in water (40 mL) achieving
the complete precipitation of pure amide 74 (9.87 g, 100%) as
a white solid: mp 115 °C (lit. mp 121 °C).26 A flask equipped
with a mechanical stirrer and containing compound 74 (7.5 g,
38 mmol) was then put in an oil bath heated at 120-130 °C
and, after complete melting of 74, AlCl3 (5.56 g, 41.7 mmol)
Table 4. HF-STO 3-21G(*) Partial Charges Calculated for
Benzo[c]quinolizin-3-ones
charge
compd N C4a C4 C3 O3
35 -0.26 0.41 -0.90 0.98 -0.62
37 -0.35 0.40 -0.87 0.92 -0.62
38 -0.30 0.17 -0.41 0.80 -0.59
40 -0.37 0.20 -0.35 0.73 -0.58
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was added in small portions and the mixure left under stirring
at 120 °C for 24 h. After cooling to room temperature, 10%
HCl (100 mL) was added dropwise and the mixture was
extracted with CH2Cl2. The organic layer was washed with
brine, water, and dried over Na2SO4. After concentration,
lactam 49 (5.63 g, 92%) was obtained as a brown solid
sufficiently pure for the next step: 1H NMR (CDCl3) ä 8.21 (s,
1 H), 7.05-6.98 (m, 2 H), 6.70-6.66 (m, 1 H), 2.98-2.91 (m, 2
H), 2.67-2.59 (m, 2 H), 2.31 (s, 3 H).
6-Chloro-3,4-dihydroquinolin-2(1H)-one (50).26 It was
prepared as reported for 49. Starting from p-chloroaniline 72
(12.76 g, 100 mmol), amide 7526 (10.9 g) was obtained in 100%
yield after recrystallization from MeOH-H2O, 1:1 (mp 120-
122 °C). The cyclization of 75 (7.3 g, 33.5 mmol) to the
corresponding lactam was carried out by heating at 140 °C
and using 2 equiv of AlCl3 (8.9 g, 66.9 mmol), obtaining 50
(5.70 g, 94%) as a pale yellow solid sufficiently pure for the
next step: mp 106 °C; 1H NMR (CDCl3) ä 8.52 (s, 1 H), 7.17-
7.10 (m, 2 H), 6.76-6.71 (m, 1 H), 3.00-2.92 (m, 2 H), 2.67-
2.60 (m, 2 H).
6-Chloro-3-methyl-3,4-dihydroquinolin-2(1H)-one (51).
A solution of aldehyde 70 (3.104 g, 16.7 mmol) and 2-(triphen-
ylphosphanylidene)propionic acid methyl ester27 (8.28 g, 23.77
mmol) in toluene (170 mL), heated at 80 °C, was stirred for 3
h. The reaction mixture was then concentrated, the crude oil
redissolved in Et2O (250 mL) and kept under vigorous stirring
for 1 h. The resulting suspension was filtered, concentrated
and the residual oil chromatographed (EtOAc-petroleum
ether, 1:4, Rf 0.52), affording cynnamate 71 (4.20 g, 90%) as
an oil: 1H NMR (CDCl3) (major diastereoisomer) ä 8.12 (d,
J ) 8.7 Hz, 1 H), 7.85 (s, 1 H), 7.49 (dd, J ) 8.7, 2.5 Hz, 1 H),
7.34 (d, J ) 2.5 Hz, 1 H), 3.85 (s, 3 H), 1.92 (s, 3 H).
The hydrogenation of 71 was then carried out in a magneti-
cally stirred 150 mL stainless steel autoclave. PtO2 (160 mg)
was added to a solution of substrate 71 (4 g, 14.4 mmol) in
AcOH (60 mL), then the reactor was purged with nitrogen,
pressurized with H2 (10 atm) and finally heated in a thermo-
stated bath at 60 °C for 14 h. The catalyst was then filtered,
the solution concentrated under vacuum and adjusted to pH
8 by addition of 0.5 N NaOH. The mixture was extracted with
CHCl3, dried over Na2SO4 and concentrated to give crude 51.
Pure 51 (2.190 g, 78%) was obtained by recrystallization from
i-Pr2O: 1H NMR (CDCl3) ä 9.82 (br s, 1 H), 7.14-7.11 (m, 2
H), 6.82 (d, J ) 9.1 Hz, 1 H), 3.00-2.83 (m, 1 H), 2.79-2.64
(m, 2 H), 1.28 (d, J ) 6.2 Hz, 3 H); 13C NMR (CDCl3) ä 175.0
(s), 135.9 (s), 127.9 (d), 127.7 (s), 127.3 (d), 125.0 (s), 116.5 (d),
34.5 (d), 33.0 (t), 15.2 (q); MS m/z (%) 195 (M+, 90), 166 (100).
4,6-Dimethyl-3,4-dihydroquinolin-2(1H)-one (52).26 It
was prepared as reported for 49. Starting from p-toluidine 73
(7.08 g, 66.0 mmol) and 3-chlorobutanoyl cholride (3.8 mL, 33
mmol), amide 76 (6.0 g) was obtained in 86% yield: 1H NMR
(CDCl3) ä 7.40 (d, J ) 8.2 Hz, 2 H), 7.21 (d, J ) 8.2 Hz, 2 H),
4.56 (m, 1 H), 2.75 (d, J ) 6.6 Hz, 2 H), 2.32 (s, 3 H), 1.62 (d,
J ) 6.6 Hz, 3 H). The cyclization of 76 (5.43 g, 25.6 mmol) to
the corresponding lactam was carried out by heating at 130
°C for 5 h and using 1 equiv of AlCl3 (3.50 g, 25.6 mmol),
obtaining 52 (4.47 g, 100%) as a pale brown solid sufficiently
pure for the next step: 1H NMR (CDCl3) ä 10.11 (br s, 1 H),
6.99-6.81 (m, 3 H), 3.07 (m, 1 H), 2.72 (dd, J ) 16.1, 5.8 Hz,
1 H), 2.41 (dd, J ) 16.1, 7.0 Hz, 1 H), 2.30 (s, 3 H), 1.29 (d,
J ) 6.9 Hz, 3 H).
6-Chloro-4-methyl-3,4-dihydroquinolin-2(1H)-one (53).26
It was prepared as reported for 49. Starting from p-chloro-
aniline 72 (8.42 g, 66.0 mmol) and 3-chlorobutanoyl chloride
(3.8 mL, 33 mmol), amide 77 (7.66 g) was obtained in
quantitative yield: 1H NMR (CDCl3) ä 7.56 (br s, 1 H), 7.47
(d, J ) 8.7 Hz, 2 H), 7.28 (d, J ) 8.7 Hz, 2 H), 4.55 (m, 1 H),
2.75 (m, 2 H), 1.61 (d, J ) 6.6 Hz, 3 H). The cyclization of 77
(4.10 g, 17.7 mmol) to the corresponding lactam was carried
out by heating at 160 °C for 3 h and using 2 equiv of AlCl3
(4.80 g, 35.3 mmol), obtaining 53 (3.46 g, 100%) as a pale
yellow solid sufficiently pure for the next step: 1H NMR
(CDCl3) ä 9.51 (br s, 1 H), 7.26-7.17 (m, 2 H), 6.81 (d, J ) 8.0
Hz, 1 H), 3.11 (m, 1 H), 2.72 (dd, J ) 16.4, 5.8 Hz, 1 H), 2.49-
2.35 (m, 1 H), 1.31 (d, J ) 7.0 Hz, 3 H).
N-(tert-Butoxycarbonyl)-3,4-dihydroquinolin-2(1H)-
one (54). To a solution of 48 (5 g, 34 mmol) in anhydrous CH2-
Cl2 (110 mL) were added Et3N (4.7 mL, 34 mmol), (BOC)2O
(8.9 g, 40.8 mmol), and DMAP (410 mg, 3.4 mmol). After
stirring for 18 h at room temperature, the solvent was
evaporated and water (200 mL) was added. The resulting
mixture was extracted with Et2O (3  150 mL), the combined
organic layers were washed with 1 M KHSO4, NaHCO3(satd),
brine, and dried over Na2SO4. After filtration and evaporation
of the solvent N-Boc derivative 54 (8.23 g, 98%) was obtained
as a white solid: mp 68-69 °C; 1H NMR (CDCl3) ä 7.22-6.93
(m, 4 H), 2.97 (t, J ) 7.0 Hz, 2 H), 2.67 (t, J ) 7.0 Hz, 2 H),
1.62 (s, 9 H); 13C NMR (CDCl3) ä 169.3 (s), 151.7 (s), 137.5 (s),
128.0 (d), 127.3 (d), 125.9 (s), 124.1 (d), 116.9 (d), 85.0 (s), 32.3
(t), 27.7 (q, 3 C), 25.5 (t); MS m/z (%) 247 (M+, 4), 147 (100),
57 (100); IR (CDCl3) 1767, 1691 cm-1.
N-(tert-Butoxycarbonyl)-6-methyl-3,4-dihydroquinolin-
2(1H)-one (55). It was prepared as reported for 54. Starting
from 49 (5.5 g, 34 mmol), pure 55 (8.3 g, 94%) was obtained
after chromatography (CHCl3, Rf 0.50) as a gummy solid: 1H
NMR (CDCl3) ä 7.20 (m, 2 H), 6.84 (d, J ) 8.0 Hz, 1 H), 2.89
(m, 2 H), 2.64 (m, 2 H), 2.29 (s, 3 H), 1.59 (s, 9 H); 13C NMR
(CDCl3) ä 168.7 (s), 151.2 (s), 134.1 (s), 133.1 (s), 128.0 (d),
127.2 (s), 125.3 (d), 116.4 (d), 84.1 (s), 31.9 (t), 27.1 (q, 3 C),
24.8 (t), 20.1 (q); MS m/z (%) 261 (M+, 2), 161 (100); IR (CDCl3)
1760, 1680 cm-1.
N-(tert-Butoxycarbonyl)-6-chloro-3,4-dihydroquinolin-
2(1H)-one (56). It was prepared as reported for 54. Starting
from 50 (6.59 g, 36.3 mmol), pure 56 (9.45 g, 92%) was obtained
after chromatography (CH2Cl2-MeOH, 30:1, Rf 0.63) as a pale
yellow solid: mp 95 °C; 1H NMR (CDCl3) ä 7.21 (m, 2 H), 6.91
(d, J ) 9.2 Hz, 1 H), 2.93 (m, 2 H), 2.66 (m, 2 H), 1.61 (s, 9 H);
13C NMR (CDCl3) ä 168.8 (s), 151.3 (s), 135.6 (s), 133.1 (s),
129.2 (d), 127.8 (s), 127.2 (d), 118.4 (s), 112.2 (d), 85.2 (s), 32.0
(t), 27.6 (q, 3 C), 25.2 (t); MS m/z (%) 181 (M+ - 100, 100); IR
(CDCl3) 1762, 1692 cm-1.
N-(tert-Butoxycarbonyl)-6-chloro-3-methyl-3,4-dihy-
droquinolin-2(1H)-one (57). It was prepared as reported for
54. Starting from 51 (1.0 g, 6.22 mmol), crude 57 (1.62 g, 88%)
was obtained sufficiently pure for the next step as a colorless
oil: 1H NMR (CDCl3) ä 7.20-7.15 (m, 2 H), 6.85 (d, J ) 9.1
Hz, 1 H), 2.85-2.62 (m, 3 H), 1.59 (s, 9 H), 1.26 (d, J ) 6.2
Hz, 3 H); 13C NMR (CDCl3) ä 171.5 (s), 151.7 (s), 135.5 (s),
129.1 (s), 127.9 (d), 127.3 (s), 127.2 (d), 118.1 (d), 85.2 (s), 35.7
(d), 33.1 (t), 27.5 (q, 3 C), 14.7 (q).
N-(tert-Butoxycarbonyl)-4,6-dimethyl-3,4-dihydroquin-
olin-2(1H)-one (58). It was prepared as reported for 54.
Starting from 52 (1.0 g, 5.23 mmol), crude 58 (1.44 g, 100%)
was obtained sufficiently pure for the next step as an oil: 1H
NMR (CDCl3) ä 7.04-6.87 (m, 2 H), 6.84-6.82 (m, 1 H), 3.07
(m, 1 H), 2.72 (dd, J ) 15.3, 5.1 Hz, 1 H), 2.44 (dd, J ) 15.3,
6.9 Hz, 1 H), 2.33 (s, 3 H), 1.60 (s, 9 H), 1.30 (d, J ) 6.9 Hz, 3
H).
N-(tert-Butoxycarbonyl)-6-chloro-4-methyl-3,4-dihy-
droquinolin-2(1H)-one (59). It was prepared as reported for
54. Starting from 53 (4.0 g, 20.4 mmol), crude 59 (6.01 g, 100%)
was obtained sufficiently pure for the next step as a pale yellow
oil: 1H NMR (CDCl3) ä 7.22-7.16 (m, 2 H), 6.92-6.88 (m, 1
H), 3.09 (m, 1 H), 2.72 (dd, J ) 15.4, 5.1 Hz, 1 H), 2.44 (dd,
J ) 15.4, 7.7 Hz, 1 H), 1.60 (s, 9 H), 1.31 (d, J ) 7.0 Hz, 3 H);
13C NMR (CDCl3) ä 167.9 (s), 151.2 (s), 134.7 (s), 132.5 (s),
129.3 (s), 127.0 (d), 126.3 (d), 118.4 (d), 85.0 (s), 39.2 (d), 30.5
(t), 27.5 (q, 3 C), 18.9 (q); MS m/z (%) 195 (M+ - 100, 89), 180
(100), 152 (73), 117 (81), 89 (46).
N-(tert-Butoxycarbonyl)-2-ethoxy-1,2,3,4-tetrahydro-
quinoline (60). To a solution of N-Boc lactam 54 (4.35 g, 17.6
mmol) in absolute ethanol (140 mL) cooled at -25 °C and
under stirring, was added NaBH4 (2.66 g, 70.4 mmol) in 6
portions during 1 h. After 4 h, the solution was adjusted to
pH 3-4 by adding slowly a 2 N HCl solution in absolute EtOH
and the resulting suspension was left under stirring at 0 °C
for 1.5 h. Then water (100 mL) was added, the mixture was
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extracted with CH2Cl2 and the organic layer washed with
NaHCO3(satd), brine, and dried over Na2SO4. After evapora-
tion of the solvent pure compound 60 (4.74 g, 96%) was
obtained as a yellow oil: 1H NMR (CDCl3) ä 7.55 (d, J ) 8 Hz,
1 H), 7.20-6.99 (m, 3 H), 5.84 (t, J ) 4.0 Hz, 1 H), 3.59 (qd,
J ) 7.0, 3.3 Hz, 2 H), 2.96-2.80 (m, 1 H), 2.74-2.60 (m, 1 H),
2.25-2.11 (m, 1 H), 2.07-1.99 (m, 1 H), 1.53 (s, 9 H); 1.13 (t,
J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä 154.3 (s), 136.6 (s), 130.8
(s), 128.8 (d), 126.3 (d), 125.6 (d), 124.4 (d), 81.9 (d), 81.7 (s),
63.3 (t), 29.8 (t), 29.0 (q, 3 C), 23.9 (t), 15.7 (q); MS m/z (%)
277 (M+, 8), 131 (100); IR (CDCl3) 1685 cm-1.
N-(tert-Butoxycarbonyl)-2-ethoxy-6-methyl-1,2,3,4-tet-
rahydroquinoline (61). It was prepared as reported for 60,
starting from 55 (2 g, 7.65 mmol) and NaBH4 (1.74 g, 45.9
mmol), but the reaction was quenched with 2 N HCl in ethanol
after 2 h and left under stirring at 0 °C for 2.5 h before the
addition of water and extraction. Pure 61 (1.37 g, 62%) was
obtained by chromatography (EtOAc-petroleum ether, 1:10,
Rf 0.45) as a colorless oil: 1H NMR (CDCl3) ä 7.43 (d, J ) 8.4
Hz, 1 H), 6.95 (m, 2 H), 5.83 (t, J ) 4.0 Hz, 1 H), 3.58 (m, 2
H), 2.84 (m, 1 H), 2.67 (m, 1 H), 2.29 (s, 3 H), 2.05 (m, 2 H),
1.53 (s, 9 H), 1.13 (t, J ) 6.9 Hz, 3 H); 13C NMR (CDCl3) ä
153.5 (s), 133.2 (s), 132.7 (s), 129.7 (s), 128.5 (d), 126.2 (d),
124.6 (d), 81.1 (d), 80.7 (s), 62.4 (t), 29.0 (t), 28.1 (q, 3 C), 23.0
(t), 20.6 (q), 14.8 (q); MS m/z (%) 291 (M+, 7), 145 (100); IR
(CDCl3) 1709 cm-1.
N-(tert-Butoxycarbonyl)-6-chloro-2-ethoxy-1,2,3,4-tet-
rahydroquinoline (62). It was prepared as reported for 60,
starting from 56 (2.9 g, 10.65 mmol) and NaBH4 (2.42 g, 63.9
mmol), but the reaction was quenched with 2 N HCl in ethanol
after 2.5 h and left under stirring at 0 °C for 2.5 h before the
addition of water and extraction. Pure 62 (2.44 g, 68%) was
obtained by chromatography (EtOAc-petroleum ether, 1:10,
Rf 0.47) as a colorless oil: 1H NMR (CDCl3) ä 7.52 (d, J ) 8.1
Hz, 1 H), 7.10 (m, 2 H), 5.81 (t, J ) 2.5 Hz, 1 H), 3.55 (m, 2
H), 2.84 (m, 1 H), 2.66 (m, 1 H), 2.11-2.01 (m, 2 H), 1.53 (s, 9
H), 1.12 (t, J ) 6.9 Hz, 3 H); 13C NMR (CDCl3) ä 153.3 (s),
134.5 (s), 131.6 (s), 128.9 (s), 128.0 (d), 126.0 (d), 125.7 (d),
81.4 (d), 81.0 (s), 62.7 (t), 28.5 (t), 28.3 (q, 3 C), 22.9 (t), 14.9
(q); MS m/z (%) 311 (M+, 6), 185 (100); IR (CDCl3) 1685 cm-1.
N-(tert-Butoxycarbonyl)-6-chloro-2-ethoxy-3-methyl-
1,2,3,4-tetrahydroquinoline (63). It was prepared as re-
ported for 60, starting from 57 (239 mg, 0.81 mmol) and NaBH4
(200 mg, 5.3 mmol), but the reaction was quenched with 2 N
HCl in ethanol after 3 h and left under stirring at 0 °C for 7
h before the addition of water and extraction. Compound 63
(240 mg, 91%) was obtained as a colorless oil sufficiently pure
for the next step as a 1:1 mixture of diastereoisomers: 1H NMR
(CDCl3) ä 7.56 (d, J ) 8.8 Hz, 1 H), 7.49 (d, J ) 8.8 Hz, 1 H),
7.13-7.01 (m, 2 H + 2 H), 5.51 (d, J ) 2.5 Hz, 1 H), 5.47 (d,
J ) 3.3 Hz, 1 H), 3.65-3.42 (m, 2 H + 2 H), 2.95 (dd, J )
16.5, 6.6 Hz, 1 H), 2.69-2.61 (m, 2 H + 2 H), 2.40-2.33 (m, 1
H), 2.18-1.94 (m, 1 H), 1.57 (s, 9 H), 1.56 (s, 9 H), 1.09 (t, J )
7.0 Hz, 3 H), 1.07 (d, J ) 5.5 Hz, 3 H), 1.06 (t, J ) 7.2 Hz, 3
H), 0.97 (d, J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä 153.9 (s),
153.1 (s), 134.0 (s), 133.8 (s), 130.4 (s), 130.3 (s), 129.4 (s), 128.7
(s), 128.4 (d), 128.2 (d), 125.9 (d), 125.7 (d), 125.5 (d, 2 C), 86.3
(d), 84.4 (d), 81.5 (s), 81.3 (s), 62.9 (t), 62.8 (t), 32.8 (d), 32.0
(d), 30.9 (t), 30.6 (t), 28.3 (q, 3 C), 28.2 (q, 3 C), 17.5 (q), 17.2
(q), 14.9 (q), 14.7 (q).
N-(tert-Butoxycarbonyl)-4,6-dimethyl-2-ethoxy-1,2,3,4-
tetrahydroquinoline (64). It was prepared as reported for
60, starting from 58 (1.44 g, 5.22 mmol) and NaBH4 (1.50 g,
39.5 mmol), but the reaction was quenched with 2 N HCl in
ethanol after 5 h and left under stirring at 0 °C for 3.5 h before
the addition of water and extraction. Compound 64 (1.49 g,
94%) was obtained as a colorless oil sufficiently pure for the
next step as a 1:1 mixture of diastereisomers: 1H NMR (CDCl3)
ä 7.42 (d, J ) 8.1 Hz, 1 H), 7.25-7.20 (m, 1 H), 7.03-6.94 (m,
2 H + 2 H), 5.85 (dd, J ) 7.7, 5.5 Hz, 1 H), 5.78 (t, J ) 4.1 Hz,
1 H), 3.78-3.47 (m, 2 H + 2 H), 3.11-2.97 (m, 1 H), 2.62-
2.43 (m, 1 H + 1 H), 2.34 (s, 3 H), 2.30 (s, 3 H), 2.13 (ddd, J )
10.3, 6.6, 3.3 Hz, 1 H), 1.81 (ddd, J ) 13.9, 9.9, 4.0 Hz, 1 H),
1.52 (s, 9 H), 1.60-1.50 (m, 1 H), 1.50 (s, 9 H), 1.31 (d, J ) 6.6
Hz, 3 H), 1.29 (d, J ) 7.3 Hz, 3 H), 1.14 (t, J ) 7.0 Hz, 3 H),
1.11 (t, J ) 6.9 Hz, 3 H).
N-(tert-Butoxycarbonyl)-6-chloro-2-ethoxy-4-methyl-
1,2,3,4-tetrahydroquinoline (65). It was prepared as re-
ported for 60, starting from 59 (2.00 g, 6.77 mmol) and NaBH4
(1.07 g, 28 mmol), but the reaction was quenched with 2 N
HCl in ethanol after 5 h and left under stirring at 0 °C for 3
h before the addition of water and extraction. Compound 65
(1.99 g, 91%) was obtained as a colorless oil sufficiently pure
for the next step as a 1:1 mixture of diastereisomers: 1H NMR
(CDCl3) ä 7.57 (d, J ) 8.0 Hz, 1 H), 7.31-7.26 (m, 1 H), 7.20-
7.07 (m, 2 H + 2 H), 5.81 (dd, J ) 7.8, 5.3 Hz, 1 H), 5.72 (t,
J ) 3.9 Hz, 1 H), 3.68-3.47 (m, 2 H + 2 H), 3.14-3.03 (m, 2
H + 2 H), 2.64-2.46 (m, 2 H), 2.16 (ddd, J ) 13.9, 6.9, 3.6 Hz,
1 H), 1.77 (ddd, J ) 13.9, 10.3, 3.7 Hz, 1 H), 1.53 (s, 9 H), 1.50
(s, 9 H), 1.31 (d, J ) 6.6 Hz, 3 H), 1.29 (d, J ) 7.0 Hz, 3 H),
1.18-1.03 (m, 3 H + 3 H).
General Procedure for the TiCl4-Promoted Cycliza-
tions. Synthesis of 1,2,3,4,5,6-Hexahydrobenzo[c]quino-
lizin-3(4aH)-one (1). A 1 M solution of TiCl4 in CH2Cl2 (28.84
mL, 28.84 mmol) was added dropwise in 10 min to a solution
of 60 (4 g, 14.42 mmol) in CH2Cl2 (72 mL) cooled at -30 °C
and under argon atmosphere, leaving under stirring for 10
min. To the resulting dark solution were then added diene 66
(3.15 mL, 17.29 mmol) and, after 30 min at room temperature,
a saturated solution of NaHCO3 (70 mL, very carefully at the
beginning). The mixture was vigorously stirred for 40 min,
then it was filtered through a Celite layer, washing with CH2-
Cl2, the two layers separated and the aqueous one extracted
with CH2Cl2. The combined organic layers were dried over Na2-
SO4, filtered and concentrated, obtaining a dark crude oil. Pure
1 (895 mg, 31%) was obtained after chromatography (EtOAc-
petroleum ether, 1:4, Rf 0.32) as a pale yellow solid: mp 53-
54 °C; 1H NMR (CDCl3) ä 7.19-7.02 (m, 2 H), 6.87 (d, J ) 8.1
Hz, 1 H), 6.74 (td, J ) 7.3, 1.1 Hz, 1 H), 4.22 (ddd, J ) 13.6,
6.2, 3.3 Hz, 1 H), 3.48 (m, 1 H), 3.17 (ddd, J ) 13.6, 11.4, 3.7
Hz, 1 H), 2.84-2.36 (m, 6 H), 2.21-2.06 (m, 1 H), 1.91-1.75
(m, 1 H); 13C NMR (CDCl3) ä 208.5 (s), 144.0 (s), 129.3 (d),
127.4 (d), 124.4 (s), 118.3 (d), 112.9 (d), 55.8 (d), 47.4 (t), 47.0
(t), 40.5 (t), 28.6 (t), 25.4 (t); MS m/z (%) 201 (M+, 100); IR
(CDCl3) 1710 cm-1.
General Procedure for the TMSOTf-Promoted Cy-
clizations. Synthesis of 8-Methyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (2). To a solution of
methyl vinyl ketone (730 mL, 9.05 mmol) in CH2Cl2 (25 mL),
cooled at 0 °C and under argon atmosphere, were added Et3N
(1.79 mL, 12.82 mmol) and, slowly, TMSOTf (2.2 mL, 11.3
mmol). After stirring 30 min, compound 61 (1.1 g, 3.77 mmol),
dissolved in CH2Cl2 (25 mL), was added followed by further
TMSOTf (0.73 mL, 3.77 mmol). The solution was allowed to
warm to room temperature and left under stirring 45 min.
Then NaHCO3(satd) (50 mL) was added and the mixture
stirred 36 h. Then water (50 mL) and CH2Cl2 (50 mL) were
added, the layers separated and the aqueous one extracted
with CH2Cl2. The combined organic layers were dried over Na2-
SO4, filtered and concentrated, obtaining a dark crude oil. Pure
2 (353 mg, 44%) was obtained after chromatography (CH2Cl2,
0.5% Et3N, Rf 0.12) as a pale yellow solid: mp 85-86 °C; 1H
NMR (CDCl3) ä 7.00-6.75 (m, 3 H), 4.20 (ddd, J ) 13.2, 6.8,
2.7 Hz, 1 H), 3.41 (m, 1 H), 3.10 (ddd, J ) 15.5, 11.8, 3.6 Hz,
1 H), 2.85-2.00 (m, 7 H), 2.25 (s, 3 H), 1.82 (m, 1 H); 13C NMR
(CDCl3) ä 208.4 (s), 141.8 (s), 129.9 (d), 127.7 (d), 127.5 (s),
124.2 (s), 113.1 (d), 56.1 (d), 47.3 (t), 47.1 (t), 40.4 (t), 29.6 (t),
25.3 (t), 20.1 (q); MS m/z (%) 215 (100); IR (CDCl3) 1710 cm-1.
8-Chloro-1,2,3,4,5,6-hexahydrobenzo[c]quinolizin-3-
(4aH)-one (3). It was prepared as reported for 1. Starting from
62 (500 mg, 1.6 mmol), pure 3 (128 mg, 34%) was obtained
after chromatography (CH2Cl2, 0.5% Et3N, Rf 0.28) as a pale
yellow gummy solid: 1H NMR (CDCl3) ä 7.09-7.01 (m, 2 H),
6.76 (d, J ) 8.8 Hz, 1 H), 4.12 (ddd, J ) 13.2, 6.5, 3.6 Hz, 1
H), 3.46 (m, 1 H), 3.17 (ddd, J ) 15.5, 11.0, 4.4 Hz, 1 H), 2.80-
2.37 (m, 6 H), 2.10 (m, 1 H), 1.80 (m, 1 H); 13C NMR (CDCl3)
ä 207.9 (s), 142.0 (s), 127.8 (d), 126.1 (d), 125.1 (s), 121.7 (s),
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113.0 (d), 55.6 (d), 46.2 (t), 45.9 (t), 39.3 (t), 27.4 (t), 25.3 (t);
MS m/z (%) 235 (100); IR (CDCl3) 1709 cm-1.
4R- and 4â-Methyl-1,2,3,4,5,6-hexahydrobenzo[c]quin-
olizin-3(4aH)-one (4 and 5). Compounds 4 and 5 were
prepared as reported for 2, starting from 60 (1.75 g, 6.31 mmol)
and employing 1-penten-3-one (1.49 mL, 15.1 mmol) for the
generation in situ of silyloxydiene 69. The 3:2 mixture (the
same ratio in the crude) of 4 and 5 (407 mg, 30%) was obtained
after chromatography (CH2Cl2, 0.5% Et3N, Rf 0.40) as an oil.
Attempts at separating the two diastereoisomers by chroma-
tography failed: 1H NMR (CDCl3) (mixture) ä 7.21-6.57 (m,
4 H + 4 H), 4.27 (ddd, J ) 13.5, 5.8, 2.5 Hz, 1 H, 4), 4.04 (m,
1 H, 5), 3.61 (t, J ) 7.0 Hz, 1 H, 5), 3.51 (ddd, J ) 9.1, 4.8, 3.3
Hz, 1 H, 5), 3.33-3.15 (m, 2 H, 4), 2.94-2.43 (m, 5 H + 5 H),
2.39-2.16 (m, 1 H), 2.06-1.81 (m, 2 H + 1 H), 1.24 (d, J ) 7
Hz, 3 H, 5), 1.12 (d, J ) 7 Hz, 3 H, 4).
4R- and 4â,8-Dimethyl-1,2,3,4,5,6-hexahydrobenzo[c]-
quinolizin-3(4aH)-one (6 and 7). Compounds 6 and 7 were
prepared as reported for 2, starting from 61 (2.00 g, 7.05 mmol)
and employing 1-penten-3-one (1.67 mL, 16.92 mmol) for the
generation in situ of silyloxydiene 69. The 7:2 (the same ratio
in the crude) mixture of 6 and 7 (485 mg, 30%) was obtained
after chromatography (CH2Cl2, 0.5% Et3N, Rf 0.20) as an oil.
Another chromatography of a small amount of the 7:2 mixture,
with the same eluant as above, provided 4R-compound 6 in
pure form as a thick oil: 1H NMR (CDCl3) ä 6.92 (m, 2 H),
6.79 (d, J ) 8.4 Hz, 1 H), 4.29 (ddd, J ) 13.0, 5.8, 2.5 Hz, 1
H), 3.15 (m, 2 H), 2.82-2.09 (m, 6 H), 2.25 (s, 3 H), 1.97 (m, 1
H), 1.08 (d, J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä 209.8 (s),
141.4 (s), 130.0 (d), 127.7 (d), 127.7 (s), 124.0 (s), 112.6 (d),
62.2 (d), 47.9 (d), 47.6 (t), 39.9 (t), 25.4 (t), 24.3 (t), 20.2 (q),
9.5 (q); MS m/z (%) 229 (100); IR (CDCl3) 1710 cm-1.
8-Chloro-4R- and 4â-methyl-1,2,3,4,5,6-hexahydroben-
zo[c]quinolizin-3(4aH)-one (8 and 9). Compounds 8 and 9
were prepared as reported for 2, starting from 62 (4.20 g, 13.47
mmol) and employing 1-penten-3-one (3.22 mL, 32.33 mmol)
for the generation in situ of silyloxydiene 69. The 4:1 (the same
ratio in the crude) mixture of 8 and 9 (731 mg, 22%) was
obtained after chromatography (CH2Cl2, 0.5% Et3N, Rf 0.11)
as pale yellow solid. Attempts of further separation by chro-
matography failed: 1H NMR (CDCl3) ä 7.00 (m, 2 H + 2 H),
6.75 (m, 1 H + 1 H), 4.29 (ddd, J ) 13.5, 5.1, 2.5 Hz, 1 H, 8),
3.91 (m, 1 H, 9), 3.55-3.30 (m, 2 H, 9), 3.20 (m, 2 H, 9), 2.90-
1.80 (m, 6 H + 6 H), 1.20 (d, J ) 7.2 Hz, 3 H, 9), 1.08 (d, J )
7.0 Hz, 3 H, 8); 13C NMR (CDCl3) (major isomer 8) ä 209.3 (s),
142.5 (s), 128.8 (d), 127.1 (d), 125.8 (s), 122.5 (s), 113.5 (d),
61.7 (d), 48.2 (d), 47.3 (t), 39.8 (t), 25.2 (t), 24.4 (t), 9.6 (q); MS
m/z (%) 249 (100); IR (CDCl3) 1713 cm-1.
8-Chloro-5R-methyl-1,2,3,4,5,6-hexahydrobenzo[c]quin-
olizin-3(4aH)-one (10). It was prepared as described for 1.
Starting from 63 (953 mg, 2.92 mmol), pure 10 (210 mg, 29%)
was obtained after chromatography (CH2Cl2, 0.5% Et3N, Rf
0.39) of the crude reaction mixture as a thick oil: 1H NMR
(CDCl3) ä 7.07 (dd, J ) 8.8, 2.6 Hz, 1 H), 6.98 (d, J ) 2.5 Hz,
1 H), 6.74 (d, J ) 8.8 Hz, 1 H), 4.15 (ddd, J ) 13.5, 5.9, 3.3
Hz, 1 H), 3.28-3.07 (m, 2 H), 2.79 (dd, J ) 15.8, 4.8 Hz, 1 H),
2.69-2.21 (m, 5 H), 1.85 (m, 1 H), 1.06 (d, J ) 6.9 Hz, 3 H);
13C NMR (CDCl3) ä 208.0 (s), 142.1 (s), 129.0 (d), 127.1 (d),
125.1 (s), 122.6 (s), 113.5 (d), 61.9 (d), 47.0 (t), 46.8 (t), 40.2
(t), 33.1 (t), 32.8 (d), 24.4 (t), 19.0 (q); MS m/z (%) 249 (M+,
100); IR (CDCl3) 1715 cm-1.
6R,8-Dimethyl-1,2,3,4,5,6-hexahydrobenzo[c]quinolizin-
3(4aH)-one (11). It was prepared as described for 1. Starting
from 64 (720 mg, 2.35 mmol), pure 11 (190 mg, 35%) was
obtained after chromatography (CH2Cl2, 0.5% Et3N, Rf 0.40)
of the crude reaction mixture as an oil: 1H NMR (CDCl3) ä
7.01-6.98 (m, 1 H), 6.94 (s, 1 H), 6.81-6.77 (m, 1 H), 4.18
(ddd, J ) 12.8, 6.5, 2.9 Hz, 1 H), 3.41 (m, 1 H), 3.09 (td, J )
12.1, 4.4 Hz, 1 H), 2.90 (m, 1 H), 2.74-2.60 (m, 1 H), 2.59-
2.33 (m, 3 H), 2.27 (s, 3 H), 1.96-1.71 (m, 2 H), 1.33 (d, J )
7.0 Hz, 3 H); 13C NMR (CDCl3) ä 208.6 (s), 141.7 (s), 129.8 (s),
128.6 (d), 127.7 (d), 127.6 (s), 113.2 (d), 53.1 (d), 47.9 (t), 47.2
(t), 40.7 (t), 36.8 (t), 28.9 (d), 22.2 (q); MS m/z (%) 229 (100);
IR (CDCl3) 1712 cm-1.
8-Chloro-6R-methyl-1,2,3,4,5,6-hexahydrobenzo[c]quin-
olizin-3(4aH)-one (12). It was prepared as described for 1.
Starting from 65 (950 mg, 2.90 mmol), pure 12 (193 mg, 27%)
was obtained after chromatography (CH2Cl2, 0.5% Et3N, Rf
0.55) of the crude reaction mixture as a thick oil: 1H NMR
(CDCl3) ä 7.09-7.06 (m, 2 H), 6.77-6.71 (m, 1 H), 4.10 (ddd,
J ) 12.9, 6.3, 3.7 Hz, 1 H), 3.51-3.40 (m, 1 H), 3.14 (ddd, J )
15.4, 11.0, 4.4 Hz, 1 H), 2.88 (m, 1 H), 2.72-2.38 (m, 4 H),
1.81 (m, 2 H), 1.31 (d, J ) 6.9 Hz, 3 H); 13C NMR (CDCl3) ä
208.0 (s), 142.7 (s), 131.6 (s), 127.4 (d), 126.9 (d), 125.9 (s),
114.0 (d), 52.7 (d), 47.8 (t), 46.7 (t), 40.5 (t), 36.4 (t), 28.9 (d),
21.6 (q); MS m/z (%) 249 (M+, 100); IR (CDCl3) 1715 cm-1.
8-Chloro-1R- and 1â-methyl-1,2,3,4,5,6-hexahydroben-
zo[c]quinolizin-3(4aH)-one (13 and 14). Compounds 13 and
14 were prepared as reported for 2, starting from 62 (2.99 g,
9.62 mmol) and employing 3-penten-2-one (2.25 mL, 23.1
mmol) for the generation in situ of silyloxydiene 68. The 1:1.5:2
crude mixture of 13, 14, and 78, was dissolved in CH2Cl2 (34
mL) and treated with 1 M TiCl4 (3.97 mL) in CH2Cl2 at room
temperature for 3 h, obtaining after usual NaHCO3(satd)
quench (45 min) a crude oil. This was chromatographed eluting
with CH2Cl2-petroleum ether, 1:1, 0.5% Et3N. The fractions
having Rf 0.23 (864 mg, 36%) contained a complex mixture of
products in which 13 and 14 were prevailing. Further attempts
of purification failed and the above mixture was thus used
directly for the next oxidative step: 1H NMR (CDCl3) ä 7.00-
6.51 (m, 3 H + 3 H), 4.60-4.40 (m, 1 H), 3.85-3.50 (m, 1 H +
1 H), 2.80-1.60 (m, 9 H + 8 H), 1.17 (d, J ) 7.1 Hz, 3 H), 1.00
(d, J ) 7.1 Hz, 3 H).
8-Chloro-4R,5R- and 4â,5R-dimethyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (15 and 16). Com-
pounds 15 and 16 were prepared as reported for 2, starting
from 63 (2.20 g, 6.75 mmol) and employing 1-penten-3-one
(1.68 mL, 16.87 mmol) for the generation in situ of silyloxy-
diene 69. The complex crude reaction mixture obtained was
chromatographed (EtOAc-petroleum ether, 1:10, 0.5% Et3N,
Rf 0.23) providing a 1:2 mixture of 15 and 16 (356 mg, 20%)
as an oil used directly in the next oxidative step: 1H NMR
(CDCl3) ä 7.12-7.01 (m, 2 H), 6.97-6.36 (m, 1 H + 1 H), 6.80
(d, J ) 8.8 Hz, 1 H), 6.70 (d, J ) 8.8 Hz, 1 H), 4.27 (ddd, J )
14.3, 5.9, 1.8 Hz, 1 H, 15), 3.96 (m, 1 H, 16), 3.30-1.85 (m, 8
H + 8 H), 1.12 (d, J ) 7.3 Hz, 3 H), 1.06 (d, J ) 7.1 Hz, 3 H),
1.05 (d, J ) 7.0 Hz, 3 H), 1.04 (d, J ) 7.0 Hz, 3 H).
A pure sample of 4R,5R-compound 15 was recovered after
Hg(OAc)2 oxidation: 1H NMR (CDCl3) ä 7.11-7.04 (m, 2), 6.79
(d, J ) 8.8 Hz, 1 H), 4.27 (ddd, J ) 14.3, 5.9, 1.8 Hz, 1 H),
3.17 (ddd, J ) 14.3, 12.5, 3.3 Hz, 1 H, 1 H), 2.98 (dd, J ) 16.5,
5.5 Hz, 1 H), 2.87 (dd, J ) 11.0, 1.8 Hz, 1 H), 2.66-2.47 (m, 1
H), 2.45-2.16 (m, 4 H), 1.05 (d, J ) 7.0 Hz, 3 H), 1.04 (d, J )
7.0 Hz, 3 H); 13C NMR (CDCl3) ä 209.0 (s), 140.7 (s), 129.9 (d),
127.0 (d), 123.6 (s), 122.5 (s), 112.7 (d), 67.2 (d), 48.3 (d), 47.0
(t), 39.4 (t), 29.6 (t), 26.8 (d), 19.4 (q), 8.8 (q); MS m/z (%) 263
(M+, 73), 192 (100); IR (CDCl3) 1701 cm-1.
4R,6R,8-Trimethyl-1,2,3,4,5,6-hexahydrobenzo[c]quin-
olizin-3(4aH)-one (17). It was prepared as reported for 2,
starting from 64 (1.5 g, 4.91 mmol) and employing 1-penten-
3-one (1.17 mL, 11.8 mmol) for the generation in situ of
silyloxydiene 69. The crude reaction mixture obtained was
chromatographed (EtOAc-petroleum ether, 1:10, 0.5% Et3N,
Rf 0.24) providing 17 (170 mg, 14%), in mixture with a minor
amount of its 4â-epimer, as an oil used directly in the next
oxidative step: 1H NMR (CDCl3) ä 7.00-6.83 (m, 2 H), 6.81-
6.75 (d, J ) 7.9 Hz, 1 H), 4.16 (ddd, J ) 14.4, 5.5, 2.0 Hz, 1
H), 3.10 (m, 2 H), 3.00-2.19 (m, 5 H), 2.29 (s, 3 H), 2.00 (m, 1
H), 1.34 (d, J ) 8.0 Hz, 3 H), 1.11 (d, J ) 6.5 Hz, 3 H).
8-Chloro-4R,6R-dimethyl-1,2,3,4,5,6-hexahydrobenzo[c]-
quinolizin-3(4aH)-one (18). It was prepared as reported for
2, starting from 65 (1.8 g, 5.5 mmol) and employing 1-penten-
3-one (1.36 mL, 13.7 mmol) for the generation in situ of
silyloxydiene 69. The crude reaction mixture obtained was
chromatographed (CH2Cl2-petroleum ether, 2:1, 0.5% Et3N,
Rf 0.47) providing 18 (200 mg, 14%), in mixture with a minor
amount of its 4â-epimer, as an oil used directly in the next
oxidation step: 1H NMR (CDCl3) ä 7.09-7.01 (m, 2 H + 2 H),
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6.77-6.69 (m, 1 H + 1 H), 4.31-4.04 (ddd, J ) 14.2, 5.7, 2.3
Hz, 1 H), 3.98-3.87 (m, 1 H), 3.50 (m, 1 H), 3.3.30-3.00 (m, 2
H + 1 H), 2.96-2.10 (m, 5 H + 3 H), 2.01-1.87 (m, 1 H + 1
H), 1.60-1.42 (m, 1 H + 1 H), 1.31 (d, J ) 6.6 Hz, 3 H), 1.28
(d, J ) 6.2 Hz, 3 H), 1.09 (d, J ) 6.2 Hz, 3 H), 1.08 (d, J ) 6.6
Hz, 3 H).
3,4,5,6-Tetrahydrobenzo[c]quinolizin-3(4aH)-one (19).
It was prepared as reported for 1, starting from 60 (4 g, 14.4
mmol) and employing Danishefsky’s diene 67 (3.29 mL, 17.3
mmol). Pure 19 (820 mg, 28%) was obtained after chromatog-
raphy (EtOAc-petroleum ether, 4:1, Rf 0.35) as a solid: mp
135-136 °C; 1H NMR (CDCl3) ä 7.75 (d, J ) 7.7 Hz, 1 H),
7.23-6.95 (m, 4 H), 5.38 (d, J ) 7.7 Hz, 1 H), 4.10-3.92 (m, 1
H), 2.83 (m 2 H), 2.58-2.52 (m, 2 H), 2.27-2.15 (m, 1 H), 1.87-
1.75 (m, 1 H); 13C NMR (CDCl3) ä 193.3 (s), 146.2 (d), 138.5
(s), 129.4 (d), 127.8 (d), 126.5 (s), 122.6 (d), 114.1 (d), 104.0
(d), 57.3 (d), 43.1 (t), 28.8 (t), 27.5 (t); MS m/z (%) 199 (M+,
100); IR (CDCl3) 1638, 1565 cm-1.
8-Chloro-5R-methyl-3,4,5,6-tetrahydrobenzo[c]quin-
olizin-3(4aH)-one (27). It was prepared as reported for 1,
starting from 63 (120 mg, 0.37 mmol) and employing Dan-
ishefsky’s diene 67 (85 íL, 0.45 mmol). Pure 27 (27 mg, 29%)
was obtained after chromatography (EtOAc-petroleum ether,
2:1, Rf 0.23) as a thick oil: 1H NMR (CDCl3) ä 7.63 (d, J ) 7.6
Hz, 1 H), 7.17 (dd, J ) 8.7, 2.5 Hz, 1 H), 7.08 (s, 1 H), 6.92 (d,
J ) 8.7 Hz, 1 H), 5.38 (d, J ) 7.6 Hz, 1 H), 3.61 (ddd, J )
15.6, 10.9, 3.4 Hz, 1 H), 2.78-2.51 (m, 2 H), 2.60-2.20 (m, 2
H), 2.00-1.76 (m, 1 H), 1.15 (d, J ) 6.5 Hz, 3 H); 13C NMR
(CDCl3) ä 193.4 (s), 146.1 (d), 137.3 (s), 128.7 (d), 128.0 (s),
127.7 (d), 127.6 (s), 115.4 (d), 104.5 (d), 63.2 (d), 41.0 (t), 36.0
(t), 33.4 (d), 17.8 (q); MS m/z (%) 247 (M+, 100); IR (CDCl3)
1645, 1570 cm-1.
Oxidation of 1,2,3,4,5,6-Hexahydrobenzo[c]quinolizin-
3(4aH)-one (1). Method A: To a solution of 1 (60 mg, 0.3
mmol) in 5% AcOH (7.5 mL) were added EDTA tetrasodium
salt (500 mg, 1.2 mmol) and Hg(OAc)2 (382 mg, 1.2 mmol)
under stirring and nitrogen atmosphere. The resulting mixture
was heated at 90 °C for 2 h. Then it was cooled to room
temperature and diluted with water (7.5 mL), extracted with
chloroform, washed with NaHCO3(satd), brine and dried over
Na2SO4. After filtration and evaporation of the solvent, the
crude obtained was chromatographed (EtOAc-petroleum ether,
4:1, 0.5% ET3N) affording pure 19 (Rf 0.38, 7 mg, 10%) and 35
(Rf 0.22, 14 mg, 20%).
Method B: To a solution of freshly prepared LDA (0.68
mmol) in THF (3.5 mL), cooled at -78 °C, was added dropwise
a solution of 1 (130 mg, 0.64 mmol) in THF (3.5 mL) followed
by TMSCl (139 íL, 1.09 mmol). The reaction mixture was
allowed to warm to room temperature and, after 1 h, DDQ
(147 mg, 0.64 mmol) was added and the mixture stirred 18 h.
Then, a saturated solution of NaHCO3 was added, the white
precipitate was filtered and the resulting solution extracted
with CH2Cl2. The organic layer was washed with brine, dried
over Na2SO4, and evaporated. The crude was chromatographed
as described above, providing isomers 19 (32 mg, 25%) and
35 (33 mg, 25%) in 1:1 ratio.
35: mp 53 °C; 1H NMR (CDCl3) ä 7.23-6.95 (m, 4 H), 5.13
(s, 1 H), 4.03 (t, J ) 7.7 Hz, 2 H), 2.85-2.75 (m, 2 H), 2.70-
2.60 (m, 4 H); 13C NMR (CDCl3) ä 191.6 (s), 159.3 (s), 139.5
(s), 128.1 (d), 127.8 (d), 127.1 (s), 122.5 (d), 113.5 (d), 100.8
(d), 45.4 (t), 35.6 (t), 30.1 (t), 24.9 (t); MS m/z (%) 199 (M+,
100); IR (CDCl3) 1630 cm-1.
Oxidation of 8-Methyl-1,2,3,4,5,6-hexahydrobenzo[c]-
quinolizin-3(4aH)-one (2). It was carried out as reported for
the oxidation of 1, method B. Starting from 2 (254 mg, 1.18
mmol), pure 20 (52 mg, 21%) and 36 (40 mg, 16%) were
obtained after chromatography, eluting first with EtOAc-
petroleum ether, 2:1, 0.5% ET3N, to recover compound 20 (Rf
0.26) and then with EtOAc-petroleum ether, 4:1, 0.5% ET3N,
to collect 36 (Rf 0.19).
20: thick oil; 1H NMR (CDCl3) ä 7.72 (d, J ) 7.7 Hz, 1 H),
7.00-6.94 (m, 3 H), 5.34 (d, J ) 7.7 Hz, 1 H), 4.00 (m, 1 H),
2.79 (m, 2 H), 2.54 (m, 2 H), 2.30 (s, 3 H), 2.21 (m, 1 H), 1.78
(m, 1 H); 13C NMR (CDCl3) ä 193.1 (s), 146.1 (d), 132.1 (s),
130.0 (d), 129.9 (s), 128.3 (d), 126.3 (s), 113.9 (d), 103.3 (d),
57.2 (d), 43.0 (t), 28.9 (t), 27.4 (t), 20.4 (q); MS m/z (%) 213
(100); IR (CDCl3) 1636, 1569 cm-1.
36: thick oil; 1H NMR (CDCl3) ä 7.15-7.05 (m, 1 H), 6.97-
6.91 (m, 2 H), 5.11 (s, 1 H), 4.00 (t, J ) 7.5 Hz, 1 H), 2.81-
2.62 (m, 6 H), 2.31 (s, 3 H); 13C NMR (CDCl3) ä 191.5 (s), 159.4
(s), 137.2 (s), 132.1 (s), 128.8 (d), 128.1 (d), 126.7 (s), 113.5 (d),
100.3 (d), 45.4 (t), 35.3 (t), 30.2 (t), 24.9 (t), 20.5 (q); MS m/z
(%) 213 (M+, 100); IR (CDCl3) 1627, 1559 cm-1.
Oxidation of 8-Chloro-1,2,3,4,5,6-hexahydrobenzo[c]-
quinolizin-3(4aH)-one (3). It was carried out as reported for
the oxidation of 1, method A, dissolving the starting material
in 8% AcOH. Starting from 3 (498 mg, 0.698 mmol), pure 21
(Rf 0.37, 34 mg, 27%) and 37 (Rf 0.14, 78 mg, 54%) were
obtained after chromatography (EtOAc-petroleum ether, 4:1,
0.5% ET3N).
21: thick oil; 1H NMR (CDCl3) ä 7.66 (d, J ) 7.7 Hz, 1 H),
7.19-7.09 (m, 2 H), 6.95 (d, J ) 8.5 Hz, 1 H), 5.37 (d, J ) 7.7
Hz, 1 H), 4.10-3.96 (m, 1 H), 2.80 (m, 2 H), 2.56-2.51 (m, 2
H), 2.25-2.17 (m, 1 H), 1.87-1.72 (m, 1 H); 13C NMR (CDCl3)
ä 193.1 (s), 145.7 (d), 137.2 (s), 129.1 (d), 128.1 (s), 127.7 (d),
115.2 (d), 104.5 (d), 57.2 (d), 43.0 (t), 28.6 (t), 27.4 (t); MS m/z
(%) 233 (M+, 100); IR (CDCl3) 1650, 1575 cm-1.
37: thick oil; 1H NMR (CDCl3) ä 7.24-7.11 (m, 2 H), 6.91
(d, J ) 8.4 Hz, 1 H), 5.14 (s, 1 H), 3.99 (t, J ) 7.7 Hz, 2 H),
2.80-2.60 (m, 4 H); 13C NMR (CDCl3) ä 191.4 (s), 158.4 (s),
138.1 (s), 128.6 (s), 127.8 (d), 127.4 (d), 127.2 (s), 114.6 (d),
101.1 (d), 45.4 (t), 35.4 (t), 29.7 (t), 24.7 (t); MS m/z (%) 233
(M+, 100); IR (CDCl3) 1639, 1568 cm-1.
Oxidation of 8-Chloro-5-methyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (10). It was carried out
as reported for the oxidation of 1, method A, dissolving the
starting material in 25% AcOH. Starting from 10 (200 mg, 0.81
mmol), pure 27 (58 mg, 29%) and 41 (86 mg, 43%) were
obtained after chromatography eluting first with EtOAc-
petroleum ether, 2:1, to collect 27 (Rf 0.32) and 41 (Rf 0.22),
and then with EtOAc-MeOH, 5:1 to recover compound 79 (Rf
0.26, 16 mg, 8%).
41: thick oil; 1H NMR (CDCl3) ä 7.16 (dd, J ) 8.8, 2.3 Hz,
1 H), 7.05 (d, J ) 2.3 Hz, 1 H), 6.87 (d, J ) 8.8 Hz, 1 H), 5.15
(s, 1 H), 3.95 (t, J ) 7.3 Hz, 1 H), 2.85 (dd, J ) 15.0, 4.7 Hz,
1 H), 2.78-2.42 (m, 4 H), 1.05 (d, J ) 7.0 Hz, 3 H); 13C NMR
(CDCl3) ä 191.8 (s), 162.5 (s), 137.7 (s), 128.5 (d), 127.4 (d),
127.2 (s, 2 C), 114.3 (d), 99.6 (d), 45.6 (t), 35.3 (t), 33.2 (d),
31.9 (t), 17.5 (q); MS m/z (%) 247 (M+, 100); IR (CDCl3) 1636,
1561 cm-1.
79: thick oil; 1H NMR (CDCl3) ä 8.03 (d, J ) 7.7 Hz, 1 H),
7.38 (s, 2 H), 7.30 (s, 1 H), 6.79 (dd, J ) 8.0, 2.5 Hz, 1 H), 6.61
(d, J ) 2.9 Hz, 1 H), 3.18-2.92 (m, 2 H), 2.68 (dd, J ) 15.0,
7.3 Hz, 1 H), 1.28 (d, J ) 7.0 Hz, 3 H); MS m/z (%) 245 (M+,
71), 202 (100).
Oxidation of 6,8-Dimethyl-1,2,3,4,5,6-hexahydrobenzo-
[c]quinolizin-3(4aH)-one (11). It was carried out as reported
for the oxidation of 1, Method A, dissolving the starting
material in 45% AcOH. Starting from 11 (160 mg, 0.70 mmol),
pure 28 (Rf 0.37, 40 mg, 25%) and 42 (Rf 0.16, 74 mg, 46%)
were obtained after chromatography eluting with EtOAc-
petroleum ether, 3:2, 0.5% Et3N.
28: thick oil; 1H NMR (CDCl3) ä 7.74 (d, J ) 7.7 Hz, 1 H),
7.00-6.93 (m, 3 H), 5.34 (d, J ) 7.7 Hz, 1 H), 4.18-3.98 (m, 1
H), 3.07-2.89 (m, 1 H), 2.59-2.53 (m, 1 H), 2.50-2.42 (m, 2
H), 2.28 (s, 3 H), 1.94 (dd, J ) 8.0, 4.6 Hz, 1 H), 1.80 (d, J )
6.9 Hz, 3 H); 13C NMR (CDCl3) ä 193.3 (s), 145.9 (d), 135.1 (s),
132.2 (s), 130.9 (s), 129.7 (d), 128.4 (s), 113.9 (d), 103.3 (d),
51.7 (d), 43.0 (t), 34.5 (t), 31.0 (d), 21.5 (q), 20.4 (q); MS m/z
(%) 227 (100); IR (CDCl3) 1632, 1569 cm-1.
42: thick oil; 1H NMR (CDCl3) ä 7.07-6.98 (m, 1 H), 6.95
(s, 1 H), 6.87 (d, J ) 8.0 Hz, 1 H), 5.10 (s, 1 H), 3.94 (t, J ) 7.7
Hz, 1 H), 2.86 (m, 1 H), 2.71-2.56 (m, 1 H), 2.62 (t, J ) 7.6
Hz, 2 H), 2.34 (dd, J ) 15.4, 7.3 Hz, 1 H), 2.28 (s, 3 H), 1.23
(d, J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä 191.5 (s), 158.4 (s),
136.4 (s), 132.3 (s), 131.7 (s), 128.0 (d), 127.3 (d), 113.8 (d),
101.2 (d), 45.4 (t), 37.4 (t), 35.6 (t), 29.4 (d), 20.6 (q), 18.7 (q);
MS m/z (%) 227 (M+, 100); IR (CDCl3) 1628, 1551 cm-1.
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Oxidation of 8-Chloro-6-methyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (12). It was carried out
as reported for the oxidation of 1, Method A, dissolving the
starting material in 50% AcOH. Starting from 12 (133 mg, 0.53
mmol), pure 29 (Rf 0.22, 35 mg, 26%) and 43 (Rf 0.14, 65 mg,
51%) were obtained after chromatography eluting with EtOAc-
petroleum ether, 3:1, 0.5% Et3N.
29: thick oil; 1H NMR (CDCl3) ä 7.68 (d, J ) 7.7 Hz, 1 H),
7.19-7.09 (m, 2 H), 6.95 (d, J ) 7.8 Hz, 1 H), 5.36 (d, J ) 7.7
Hz, 1 H), 4.21-4.03 (m, 1 H), 3.08-2.97 (m, 1 H), 2.58-2.44
(m, 2 H), 1.97-1.89 (m, 2 H), 1.27 (d, J ) 6.9 Hz, 3 H); 13C
NMR (CDCl3) ä 193.1 (s), 145.3 (d), 136.2 (s), 132.6 (s), 128.8
(d), 127.6 (d), 127.4 (s), 115.2 (d), 104.5 (d), 51.6 (d), 43.0 (t),
34.2 (t), 30.9 (d), 21.3 (q); MS m/z (%) 247 (M+, 100); IR (CDCl3)
1646, 1568 cm-1.
43: thick oil; 1H NMR (CDCl3) ä 7.23-7.13 (m, 2 H), 6.91
(d, J ) 8.8 Hz, 1 H), 5.14 (s, 1 H), 3.99 (t, J ) 7.7 Hz, 2 H),
2.93 (m, 1 H), 2.71-2.68 (m, 1 H), 2.65 (t, J ) 7.6 Hz, 2 H),
2.37 (dd, J ) 15.0, 7.7 Hz, 1 H), 1.27 (d, J ) 6.9 Hz, 3 H); 13C
NMR (CDCl3) ä 191.4 (s), 157.5 (s), 137.4 (s), 133.5 (s), 127.6
(s), 127.4 (d), 126.5 (d), 114.9 (d), 102.0 (d), 45.5 (t), 37.0 (t),
35.5 (t), 29.4 (d), 18.4 (q); MS m/z (%) 247 (M+, 100); IR (CDCl3)
1640, 1567 cm-1.
Oxidation of 8-Chloro-1-methyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (13 and 14). It was
carried out as reported for the oxidation of 1, method B.
Starting from the 13-14 mixture (687 mg, 2.75 mmol), pure
44 (Rf 0.42, 122 mg, 18%) was obtained after chromatography,
eluting with EtOAc-petroleum ether, 2:1, 0.5% ET3N, while
compound 30 (Rf 0.55, 61 mg, 9%) was obtained in 1:1 mixture
with 44. Further attempts of separate 30 from 44 by chroma-
tography failed.
The oxidation was also performed according to method A,
dissolving the starting material in 45% AcOH. Starting from
the 13-14 mixture (120 mg, 0.48 mmol), pure 44 (68 mg, 57%)
was obtained after chromatography (the same eluant as
above).
30: 1H NMR (CDCl3) (from the mixture with 44) ä 7.26-
7.13 (m, 2 H), 6.87 (d, J ) 9.5 Hz, 1 H), 5.39 (s, 1 H), 4.10-
3.90 (m, 1 H), 3.20-3.00 (m, 1 H), 2.75-2.56 (m, 3 H), 1.82-
1.70 (m, 2 H), 1.26 (s, 3 H).
44: thick oil; 1H NMR (CDCl3) ä 7.24-7.10 (m, 2 H), 6.95
(d, J ) 8.2 Hz, 1 H), 5.13 (s, 1 H), 4.51 (m, 1 H), 3.05-2.93 (m,
1 H), 2.84-2.55 (m, 4 H), 2.38-2.30 (m, 1 H), 1.33 (d, J ) 6.6
Hz, 3 H); 13C NMR (CDCl3) ä 190.9 (s), 155.7 (s), 137.3 (s),
128.8 (s), 128.7 (d), 127.7 (d), 123.5 (s), 114.7 (d), 100.5 (d),
51.5 (d), 41.9 (t), 30.00 (t), 25.1 (t), 15.0 (q); MS m/z (%) 247
(M+, 100); IR (CDCl3) 1637, 1567 cm-1.
Oxidation of 4-Methyl-1,2,3,4,5,6-hexahydrobenzo[c]-
quinolizin-3(4aH)-one (4 and 5). It was performed as
reported for the oxidation of 1, method A, dissolving the
starting material in 5% AcOH. Starting from the 3:2 mixture
of 4 and 5 (79 mg, 0.37 mmol), pure 38 (Rf 0.29, 30 mg, 38%)
was obtained after chromatography eluting with EtOAc-
petroleum ether, 2:1, 0.5% Et3N. A small amount of 80 (9 mg,
12%) was also obtained after chromatography by washing the
silica gel with MeOH.
The oxidation was also performed according to method B.
Starting from the 3:2 mixture of 4 and 5 (56 mg, 0.26 mmol),
pure 22 (Rf 0.59, 13 mg, 22%) and 23 (Rf 0.36, 13 mg, 22%)
were obtained after chromatography as thick oils, eluting with
EtOAc-petroleum ether, 2:1, 0.5% ET3N.
38: mp 88-89 °C; 1H NMR (CDCl3) ä 7.25-6.94 (m, 4 H),
3.93 (t, J ) 7.7 Hz, 2 H), 2.80-2.63 (m, 6 H), 1.83 (s, 3 H); 13C
NMR (CDCl3) ä 190.7 (s), 156.3 (s), 140.5 (s), 127.9 (d), 127.8
(d), 126.7 (s), 121.8 (d), 112.8 (d), 105.9 (s), 45.0 (t), 35.5 (t),
26.3 (t), 24.8 (t), 10.1 (q); MS m/z (%) 213 (M+, 98), 212 (100);
IR (CDCl3) 1622, 1553 cm-1.
22: 1H NMR (CDCl3) ä 7.70 (d, J ) 7.7 Hz, 1 H), 7.23-6.95
(m, 4 H), 5.40 (d, J ) 7.7 Hz, 1 H), 3.63 (ddd, J ) 12.4, 12.4,
4.4 Hz, 1 H), 2.89-2.77 (m, 2 H), 2.45-2.31 (m, 2 H), 1.82-
1.61 (m, 1 H), 1.23 (d, J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä
195.3 (s), 145.8 (d), 139.2 (s), 129.0 (d), 127.8 (d), 126.8 (s),
122.5 (d), 114.5 (d), 103.4 (d), 62.7 (d), 45.1 (d), 27.5 (t, 2 C),
10.6 (q); MS m/z (%) 213 (M+, 100); IR (CDCl3) 1642, 1569 cm-1.
23: 1H NMR (CDCl3) ä 7.67 (d, J ) 7.7 Hz, 1 H), 7.24-6.97
(m, 4 H), 5.30 (dd, J ) 7.7, 1.1 Hz, 1 H), 4.10-3.99 (dt, J )
12.4, 3.5 Hz, 1 H), 2.87-2.80 (m, 2 H), 2.42-2.36 (m, 1 H),
2.10-1.87 (m, 2 H), 1.04 (d, J ) 7.3 Hz, 3 H); 13C NMR (CDCl3)
ä 195.2 (s), 145.7 (d), 139.5 (s), 129.2 (d), 127.9 (d), 127.3 (s),
122.7 (d), 114.5 (d), 102.2 (d), 60.2 (d), 44.3 (d), 27.7 (t), 25.3
(t), 10.1 (q); MS m/z (%) 213 (M+, 100); IR (CDCl3) 1634 cm-1.
80: 1H NMR (CDCl3) ä 7.89 (d, J ) 7.6 Hz, 1 H), 7.40-7.00
(m, 4 H), 6.51 (d, J ) 7.6 Hz, 1 H), 2.93 (m, 4 H), 2.18 (s, 3 H);
MS m/z (%) 211 (M+, 25), 210 (100).
Oxidation of 4,8-Dimethyl-1,2,3,4,5,6-hexahydrobenzo-
[c]quinolizin-3(4aH)-one (6 and 7). It was carried out as
reported for the oxidation of 1, method A, dissolving the
starting material in 8% AcOH. Starting from the 7:2 mixture
of 6 and 7 (151 mg, 0.31 mmol), pure 39 (Rf 0.51, 50 mg, 71%)
was obtained after chromatography eluting with EtOAc-
petroleum ether, 2:1, 0.5% Et3N.
The oxidation was also performed according to method B.
Starting from the 7:2 mixture of 6 and 7 (243 mg, 1.06 mmol),
pure 24 (Rf 0.60, 56 mg, 23%) and 25 (Rf 0.28, 56 mg, 23%)
were obtained after chromatography, eluting with EtOAc-
petroleum ether, 2:1, 0.5% ET3N.
39: 1H NMR (CDCl3) ä 7.06-6.83 (m, 3 H), 3.91 (t, J ) 7.7
Hz, 2 H), 2.73-2.61 (m, 6 H), 2.30 (s, 3 H), 1.82 (s, 3 H); 13C
NMR (CDCl3) ä 190.3 (s), 156.8 (s), 138.1 (s), 131.4 (s), 128.4
(d), 128.0 (d), 126.6 (s), 112.8 (d), 105.3 (s), 45.0 (t), 35.3 (t),
26.4 (t), 24.7 (t), 20.4 (q), 10.0 (q); MS m/z (%) 227 (M+, 100);
IR (CDCl3) 1652, 1573 cm-1.
24: thick oil; 1H NMR (CDCl3) ä 7.66 (d, J ) 7.7 Hz, 1 H),
6.93 (m, 3 H), 5.35 (d, J ) 7.7 Hz, 1 H), 3.60 (ddd, J ) 12.4,
12.4, 4.4 Hz, 1 H), 2.78 (m, 2 H), 2.33 (m, 2 H), 2.29 (s, 3 H),
1.70 (m, 1 H), 1.21 (d, J ) 7.3 Hz, 3 H); 13C NMR (CDCl3) ä
195.1 (s), 145.8 (d), 136.6 (s), 132.0 (s), 129.5 (d), 128.2 (d),
126.6 (s), 114.3 (d), 102.6 (d), 62.5 (d), 44.8 (d), 27.4 (t), 27.3
(t), 20.4 (q), 10.6 (q); MS m/z 227 (M+, 100); IR (CDCl3) 1644,
1572 cm-1.
25: thick oil; 1H NMR (CDCl3) ä 7.70 (d, J ) 7.4 Hz, 1 H),
6.99 (m, 3 H), 5.34 (d, J ) 7.4 Hz, 1 H), 4.02 (dt, J ) 12.7, 3.2
Hz, 1 H), 2.82 (m, 2 H), 2.40 (m, 1 H), 2.30 (s, 3 H), 2.03-1.85
(m, 2 H), 1.03 (d, J ) 7.4 Hz, 3 H); 13C NMR (CDCl3) ä 198.0
(s), 145.6 (d), 137.1 (s), 132.3 (s), 129.7 (d), 128.4 (d), 127.1 (s),
114.4 (d), 101.6 (d), 60.2 (d), 44.3 (d), 27.7 (t), 25.4 (t), 20.5 (q),
10.1 (q); MS m/z 227 (M+, 100); IR (CDCl3) 1636, 1501 cm-1.
Oxidation of 8-Chloro-4-methyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (8 and 9). It was carried
out as reported for the oxidation of 1, method A, dissolving
the starting material in 8% AcOH. Starting from the 4:1
mixture of 8 and 9 (212 mg, 0.85 mmol), pure 40 (Rf 0.18, 73
mg, 35%) was obtained after chromatography eluting with
EtOAc-petroleum ether, 2:1, 0.5% Et3N.
The oxidation was also performed according to method B.
Starting from the 4:1 mixture of 8 and 9 (333 mg, 1.33 mmol),
pure 26 (Rf 0.50, 47 mg, 18%) was obtained after chromatog-
raphy, eluting with EtOAc-petroleum ether, 2:1, 0.5% ET3N.
40: mp 108-110 °C; 1H NMR (CDCl3) ä 7.23-7.11 (m, 2
H), 6.87 (d, J ) 8.8 Hz, 1 H), 3.90 (t, J ) 7.5 Hz, 2 H), 2.76-
2.64 (m, 6 H), 1.82 (s, 3 H); 13C NMR (CDCl3) ä 190.6 (s), 155.4
(s), 139.0 (s), 128.3 (s), 127.7 (d), 127.3 (d), 126.5 (s), 113.9 (d),
106.4 (s), 45.1 (t), 35.3 (t), 26.1 (t), 24.7 (t), 10.1 (q); MS m/z
(%) 247 (M+, 100); IR (CDCl3) 1648, 1569 cm-1.
26: thick oil; 1H NMR (CDCl3) ä 7.60 (d, J ) 7.3 Hz, 1 H),
7.26-7.11 (m, 2 H), 6.97 (d, J ) 8.8 Hz, 1 H), 5.30 (dd, J )
7.7, 1.1 Hz, 1 H), 4.03 (ddd, J ) 12.8, 12.8, 3.6 Hz, 1 H), 2.84-
2.76 (m, 2 H), 2.42-2.36 (m, 1 H), 2.08-1.82 (m, 2 H), 1.02 (d,
J ) 7.0 Hz, 3 H); 13C NMR (CDCl3) ä 197.9 (s), 145.2 (d), 138.2
(s), 131.0 (s), 128.9 (d), 127.8 (d), 127.4 (s), 115.7 (d), 102.8
(d), 60.1 (d), 44.2 (d), 27.6 (t), 25.2 (t), 10.0 (q); MS m/z (%)
247 (M+, 100); IR (CDCl3) 1661, 1568 cm-1.
Oxidation of 8-Chloro-4,5-dimethyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (15 and 16). It was
performed as reported for the oxidation of 1, method A,
dissolving the starting material in 50% AcOH. Starting from
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the 1:2 mixture of 15 and 16 (153 mg, 0.6 mmol), the crude
was chromatographed eluting first with EtOAc-petroleum
ether, 3:2, 0.1% Et3N, obtaining a mixture of isomers 31 and
32 (Rf 0.39, 17 mg, 11%), and then with EtOAc-petroleum
ether, 3:1, 0.1% Et3N, affording compound 45 (Rf 0.32, 22 mg,
14%). Two successive chromatographies of the first fraction
(EtOAc-petroleum ether, 2:1, 0.1% Et3N) allowed the partial
separation of 31 (4 mg, 3%) and 32 (8 mg, 6%), compound 31
and 32 being 98% and 75% pure, respectively, by GLC
analysis.
45: thick oil; 1H NMR (CDCl3) ä 7.20 (dd, J ) 8.8, 2.6 Hz,
1 H), 7.11 (s, 1 H), 6.25 (d, J ) 8.8 Hz, 1 H), 4.09-3.95 (m, 1
H), 3.86-3.62 (m, 1 H), 3.28 (ddd, J ) 6.9, 4.7, 1.8 Hz, 1 H),
2.99 (dd, J ) 15.0, 4.7 Hz, 1 H), 2.84-2.65 (m, 1 H), 2.60-
2.47 (m, 2 H), 1.87 (s, 3 H), 0.90 (d, J ) 7.0 Hz, 3 H); 13C NMR
(CDCl3) ä 191.2 (s), 158.7 (s), 138.4 (s), 128.9 (d), 127.4 (d),
126.7 (s), 126.0 (s), 113.7 (d), 105.7 (s), 45.3 (t), 35.4 (t), 31.6
(d), 29.3 (t), 15.6 (q), 9.5 (q); MS m/z (%) 261 (M+, 100); IR
(CDCl3) 1628, 1554 cm-1.
31: oil; 1H NMR (CDCl3) ä 7.31 (d, J ) 7.7 Hz, 1 H), 7.15
(m, 2 H), 7.00 (d, J ) 8.8 Hz, 1 H), 5.24 (d, J ) 7.7 Hz, 1 H),
3.14 (dd, J ) 8.5, 8.4 Hz, 1 H), 2.90 (dd, J ) 16.1, 5.1 Hz, 1
H), 2.61 (t, J ) 7.3 Hz, 1 H), 2.54-2.48 (m, 1 H), 2.47-2.43
(m, 1 H), 1.31 (d, J ) 7.0 Hz, 3 H), 1.03 (d, J ) 6.6 Hz, 3 H);
13C NMR (CDCl3) ä 198.1 (s), 145.6 (d), 138.2 (s), 128.7 (s),
128.5 (d), 127.8 (d), 115.7 (d), 102.7 (d), 66.1 (d), 41.8 (d), 36.0
(t), 29.8 (d), 17.3 (q), 9.51 (q); MS m/z (%) 261 (M+, 100); IR
(CDCl3) 1637, 1568 cm-1.
32: oil; 1H NMR (CDCl3) ä 7.58 (d, J ) 7.7 Hz, 1 H), 7.20
(dd, J ) 8.5, 2.6 Hz, 1 H), 7.09 (s, 1 H), 6.95 (d, J ) 8.5 Hz, 1
H), 5.31 (dd, J ) 7.7, 1.1 Hz, 1 H), 3.65 (dd, J ) 11.4, 3.0 Hz,
1 H), 2.72 (dd, J ) 15.3, 3.6 Hz, 1 H), 2.59-2.44 (m, 2 H),
2.08-1.85 (m, 1 H), 1.14 (d, J ) 6.6 Hz, 3 H), 0.98 (d, J ) 7.3
Hz, 3 H).
Oxidation of 4,6,8-Trimethyl-1,2,3,4,5,6-hexahydroben-
zo[c]quinolizin-3(4aH)-one (17). It was performed as re-
ported for the oxidation of 1, method A, dissolving the starting
material in 50% AcOH. Starting from 17 (170 mg, 0.7 mmol),
pure 46 (Rf 0.21, 45 mg, 27%) was obtained after chromatog-
raphy eluting with EtOAc-petroleum ether, 1:2, 1% Et3N. By
the same chromatography a fraction (Rf 0.37) containing
compound 33 (46 mg, 27%) in mixture with minor amounts of
some unidentified compounds was also obtained and further
attempts of purification were not successful.
46: thick oil; 1H NMR (CDCl3) ä 7.05-6.94 (m, 2 H), 6.87-
6.83 (m, 1 H), 3.91 (t, J ) 7.4 Hz, 2 H), 2.96-2.86 (m, 1 H),
2.74-2.64 (m, 1 H), 2.64 (t, J ) 7.6 Hz, 2 H), 2.49 (dd, J )
15.4, 7.7 Hz, 1 H), 2.31 (s, 3 H), 1.82 (s, 3 H), 1.29 (d, J ) 6.9
Hz, 3 H); 13C NMR (CDCl3) ä 190.4 (s), 155.5 (s), 137.3 (s),
131.4 (s), 131.1 (s), 127.7 (d), 126.6 (d), 112.9 (d), 106.0 (s),
45.0 (t), 35.4 (t), 33.7 (t), 29.1 (d), 20.5 (q), 18.4 (q), 10.0 (q);
MS m/z (%) 241 (M+, 91), 226 (100); IR (CDCl3) 1628, 1561
cm-1.
33: brown thick oil; 1H NMR (CDCl3) ä 7.68 (d, J ) 7.7 Hz,
1 H), 7.25-6.80 (m, 3 H), 5.35 (d, J ) 7.7 Hz, 1 H), 3.69 (ddd,
J ) 16.8, 13.2, 4.0 Hz, 1 H), 3.00 (m, 1 H), 2.80-2.00 (m, 2 H),
2.32 (s, 3 H), 1.80 (m, 1 H), 1.18 (d, J ) 6.6 Hz, 3 H), 1.16 (d,
J ) 7.0 Hz, 3 H).
Oxidation of 8-Chloro-4,6-dimethyl-1,2,3,4,5,6-hexahy-
drobenzo[c]quinolizin-3(4aH)-one (18). It was performed
as reported for the oxidation of 1, method A, dissolving the
starting material in 50% AcOH. Starting from 18 (170 mg, 0.7
mmol), pure 47 (Rf 0.21, 68 mg, 34%) was obtained after
chromatography eluting with EtOAc-petroleum ether, 1:3, 1%
Et3N, together with a fraction containing compound 34 (Rf 0.29,
20 mg, 10%) in mixture with other unidentified compounds.
47: thick oil; 1H NMR (CDCl3) ä 7.19-7.09 (m, 2 H), 6.82
(d, J ) 8.4 Hz, 1 H), 3.89 (t, J ) 7.3 Hz, 2 H), 2.91 (m, 1 H),
2.70 (dd, J ) 15.5, 4.4 Hz, 1 H), 2.65 (t, J ) 7.3 Hz, 2 H), 2.45
(dd, J ) 15.4, 8.0 Hz, 1 H), 1.80 (s, 3 H), 1.28 (d, J ) 7.0 Hz,
3 H); 13C NMR (CDCl3) ä 190.5 (s), 154.5 (s), 138.3 (s), 132.9
(s), 127.1 (d), 126.8 (d), 125.8 (d), 114.1 (d), 107.0 (s), 45.0 (t),
35.4 (t), 33.4 (t), 29.1 (d), 18.1 (q), 10.0 (q); MS m/z (%) 261
(M+, 74), 246 (100); IR (CDCl3) 1633, 1564 cm-1.
34: 1H NMR (CDCl3) ä 7.63 (d, J ) 7.7 Hz, 1 H), 7.30-7.00
(m, 2 H), 6.93 (d, J ) 8.7 Hz, 1 H), 5.39 (d, J ) 7.7 Hz, 1 H),
3.73 (ddd, J ) 16.5, 13.6, 4.4 Hz, 1 H), 3.04 (m, 1 H), 2.80-
2.00 (m, 2 H), 1.85 (m, 1 H), 1.18 (d, J ) 7.2 Hz, 3 H), 1.16 (d,
J ) 7.3 Hz, 3 H).
4-Methyl-2,3,5,6-tetrahydrobenzo[c]quinolizin-3(1H)-
oneâHCl Salt (81). Compound 38 (83 mg, 0.39 mmol) was
dissolved in a HCl(g) saturated solution in anhydrous MeOH
(5 mL), and after stirring 30 min, the solvent was evaporated
and the yellow residue 81 (97 mg, 100%) dried under high
vacuum: mp 139-145 °C; 1H NMR (CDCl3) ä 7.40-7.08 (m, 4
H), 4.08 (t, J ) 8.2 Hz, 2 H), 2.80 (s, 4 H), 2.72 (t, J ) 8.15 Hz,
2 H), 1.78 (s, 3 H).
8-Chloro-4-methyl-1,2,3,4,5,6-hexahydrobenzo[c]quin-
olizin-3(4aH)-oneâHCl Salt (82). It was prepared as de-
scribed for compound 81. Starting from 40 (250 mg, 1 mmol)
compound 82 (282 mg, 100%) was obtained as yellow solid:
1H NMR (d6-DMSO) ä 7.00 (m, 2 H), 6.80 (d, J ) 7.8 Hz, 1 H),
3.79 (t, J ) 8.0 Hz, 2 H), 2.81 (m, 4 H), 2.72 (t, J ) 8.0 Hz, 2
H), 1.79 (s, 3 H).
Inhibition Tests toward Recombinant 5RR-1 and 5RR-
2. Cell routinary treatment: CHO 1827 (transfected with
5RR-1) and CHO 1829 (transfected with 5RR-2) cells were
maintained in Ham’s nutrient mixture F12 supplemented with
5% of fetal bovine serum. Medium was replaced two or three
times a week. At confluence, cells were washed with PBS
(phosphate-buffered saline) without Ca2+ and Mg2+ and split
with a solution of trypsin-EDTA. Cells were maintained in a
fully humidified incubator with 95% air and 5% CO2 at 37 °C.
To set up the experiments CHO 1827 (5RR-1) and CHO 1829
(5RR-2) cells were trypsinized, counted by hemocytometer and
seeded in 24-well plates at a density of 50 000 cells/well in
Ham’s nutrient mixture F-12 supplemented with 5% fetal
bovine serum until the day after.
Stock and working solution of inhibitors: Stock solu-
tions of the inhibitors were prepared at a concentration of 1
mg/mL in ethanol. To verify the stability and purity of our
inhibitors, we tested the stock solutions by GC/MS. These
solutions resulted unchanged after 1 year from the prepara-
tion. To avoid any possible alteration of the inhibitor solutions
at the lowest concentrations, working solutions at concentra-
tion below 1 mg/mL were freshly prepared and used within
15 days.
Inhibition test: Cells were incubated for 30 min at 37 °C
in a 5% CO2 incubator in a medium containing 2 íM testos-
terone (T/[3H]T ) 100/1) for the 5RR-1 assay or 0.2 íM for the
5RR-2 assay and the inhibitor in a concentration range from
10-5 to 10-9 M. Substrate and inhibitor were added in ethanol
(1% of the final volume). Medium was removed and extracted
with 3 mL of ethyl acetate. After freezing of the aqueous layer,
the organic phase was removed and evaporated. Samples were
supplemented with T and DHT as carriers (20 íL of a solution
containing 2 mg/mL of T and DHT) and steroids were
separated on TLC silica plates using CH2Cl2-Et2O 85/15 as
eluant. Steroids were visible under UV light, [2-(p-toluidino)-
naphthalene-6-sulfonic acid enhancer (TNS) was necessary to
identify DHT]. Lanes corresponding to T and DHT were
scraped and silica extracted with 2 mL of ethyl acetate. After
30 min ethyl acetate was counted in a â-counter with 5 mL of
scintillation liquid. The percentage of conversion of T into DHT
is calculated as follows: C% ) [DHT counts/(T counts + DHT
counts)]  100. The percentage of conversion at each concen-
tration of the inhibitor was normalized to the control (percent
of conversion without the inhibitor) and data were processed
with the program ALLFIT using the four-parameter logistic
equation to calculate the IC50 values. This program allows the
statistical comparison of different inhibition curves through
the F-test giving a probability p value. With this method it
was possible to compare the inhibitory potency of different
inhibitors. Generally, two different compounds were tested
simultaneously toward the two isozymes, using finasteride as
a control inhibitor in each experiment. The total recovery of
steroids was 90-100%, indicating that under the above
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conditions T and DHT are no further metabolized by other
enzymatic systems.
Inhibition Tests toward Native 5RR-1 and 5RR-2.
Human prostate homogenate preparation: Human benign
prostatic hyperplastic tissues were obtained from different
patients undergoing surgical prostatectomy. Patients had not
been previously treated with finasteride. Tissues were frozen
in liquid nitrogen immediately after surgical asportation and
stored at -80 °C until the assay. Prostatic homogenate was
obtained from 4-5 surgical pieces using a Potter homogenizer
in a 5:1 (v:w) buffer (50 mM Tris, pH 7.4, 61 mM NaCl, 1.5
mM KCl, 1 mM MgCl2â6H2O, 1 mM fumaric acid, 15 mM
nicotinamide, 0.25 mM sucrose, 1 mM PMSF) working at 4
°C. The homogenate was filtered through a nylon membrane,
fractionated and stocked at -80 °C.
Human scalp homogenate preparation: Human scalp
tissues were obtained from the neurosurgery division of our
hospital. The human scalp homogenate was prepared as
described for the prostate homogenate.
Experimental conditions of the assay: (a) Prostate
tissue: Experimental conditions were: 0.1 mg of protein per
tube, incubation time 30 min, NADPH 250 íM in a final
volume of 1 mL. Testosterone concentration was 50 nM and
inhibitors were tested in the range 10-9-10-5 M. At the end
of the incubation, samples were extracted with 3 mL of ethyl
acetate and processed according to the method described in
the previous paragraph
(b) Scalp tissue: Experimental conditions were: 0.1 mg of
protein per tube, incubation time 30 min, NADPH 500 íM in
a final volume of 0.1 mL. Testosterone concentration was 1
íM, a constant amount (10 nM) of finasteride was used to block
5RR-2, and inhibitors were tested in the range 10-9-10-5 M.
At the end of the incubation, samples were extracted with 3
mL of ethyl acetate and processed according to the method
described previously.
Evaluation of the Mechanism of Action. The experi-
ments were performed using two 24-well plates with 50 000
cells/well. In the first hour of the experiment the two plates
were treated as follows: in control wells, cells were incubated
with a medium containing the substrate testosterone 1 íM;
and in test wells, the effect of the inhibitor was monitored
using a medium supplemented with the substrate (1 íM) and
the inhibitor at a concentration close to the calculated IC50.
In the first plate the enzymatic activity was evaluated at
different times (after 10, 20, 40 and 60 min, respectively) by
withdrawing the medium, extracting it with ethyl acetate and
determining the percent of conversion. After 60 min of incuba-
tion the medium of the second plate (treated as the first plate
for the first 60 min) was withdrawn, cells were washed with
medium and then fresh medium containing the substrate but
not the inhibitor was added. The enzymatic activity was again
monitored at different times after the wash out (after 10, 20,
40 and 60 min, respectively). If in the second phase of the
experiment, when the medium without inhibitor was em-
ployed, the enzyme activity was restored to the control level,
the mechanism of action of the inhibitor was considered
reversible.
Ki Determination. CHO 1827 (5RR-1) cells were plated in
24-well plates at a density of 50 000 cells/well in Ham’s
nutrient mixture F-12 supplemented with 5% fetal bovine
serum. Cells were incubated for 60 min at 37 °C in a 5% CO2
incubator in a medium containing respectively testosterone
and [3H]testosterone 0.2-400 íM and inhibitors at three
different concentrations close to the IC50 value. Medium was
removed and extracted with 3 mL of ethyl acetate. After
freezing of the aqueous layer, the organic phase was removed
and evaporated. Samples were processed as described for the
IC50 determination and the percent of conversion was calcu-
lated. Data were processed with the program GRAFIT41 to
calculate the Ki values. The Eadie-Hofstee transformation of
the curves shows the mechanism of action.
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